The relationship between controllability, optimal testing resource allocation, and incubation-latent period mismatch as revealed by COVID-19

Jeffery Demers^{1,2,*}, William F. Fagan², Sriya Potluri², and Justin M. Calabrese^{1,2,3}

Center for Advanced Systems Understanding (CASUS), Helmholtz-Zentrum Dresden-Rosendorf (HZDR), Görlitz, Germany

Dept. of Biology, University of Maryland, College Park, MD, USA

Dept. of Ecological Modelling, Helmholtz Centre for Environmental Research-UFZ,

Leipzig, Germany

*Corresponding author; Email: jdemers@umd.edu

¹ Abstract

 The severe shortfall in testing supplies during the initial COVID-19 outbreak and ensu- ing struggle to manage the pandemic have affirmed the critical importance of optimal supply- constrained resource allocation strategies for controlling novel disease epidemics. To address the challenge of constrained resource optimization for managing diseases with complications like pre- and asymptomatic transmission, we develop an integro partial differential equation compartmental disease model which incorporates realistic latent, incubation, and infectious pe- riod distributions along with limited testing supplies for identifying and quarantining infected individuals. Our model overcomes the limitations of typical ordinary differential equation com- partmental models by decoupling symptom status from model compartments to allow a more realistic representation of symptom onset and presymptomatic transmission. To analyze the influence of these realistic features on disease controllability, we find optimal strategies for re- ducing total infection sizes that allocate limited testing resources between 'clinical' testing, which targets symptomatic individuals, and 'non-clinical' testing, which targets non-symptomatic in- dividuals. We apply our model not only to the original, delta, and omicron COVID-19 variants, but also to generically parameterized disease systems with varying mismatches between latent and incubation period distributions, which permit varying degrees of presymptomatic transmis- sion or symptom onset before infectiousness. We find that factors that decrease controllability generally call for reduced levels of non-clinical testing in optimal strategies, while the relationship between incubation-latent mismatch, controllability, and optimal strategies is complicated. In particular, though greater degrees of presymptomatic transmission reduce disease controllabil- ity, they may increase or decrease the role of non-clinical testing in optimal strategies depending on other disease factors like transmissibility and latent period length. Importantly, our model allows a spectrum of diseases to be compared within a consistent framework such that lessons learned from COVID-19 can be transferred to resource constrained scenarios in future emerging epidemics and analyzed for optimality.

 Keywords: Testing Quarantine Control, Optimal Resource Allocation, Presymptomatic Trans-mission, Latent Period, Incubation Period, Age of Infection

1 Introduction

 Since its declaration as a global pandemic in March 2020 [\(1\)](#page-46-0), COVID-19 has caused over 600 million cumulative infections and 6 million deaths [\(2\)](#page-46-1). This loss of life and productivity together with ubiquitous lockdowns and mobility restrictions have resulted in devastating socioeconomic consequences worldwide [\(3,](#page-46-2) [4\)](#page-46-3). The particularly severe costs of lockdowns underscore the need for effective large scale test-trace-quarantine programs to combat emerging disease epidemics and save lives while keeping society open and functioning. Unfortunately, for an epidemic caused by a novel pathogen, testing supplies and health care infrastructure may be inadequate to meet demand as health agencies struggle to implement new techniques and technologies at population-wide scales. During the initial phases of the COVID-19 pandemic, for example, testing capacities fell well-short of the levels required to monitor populations and test all suspected cases, while processing delays $\frac{40}{100}$ limited the usefulness of the tests that were actually available $(5, 6)$ $(5, 6)$ $(5, 6)$. Even now, 3 years after the ⁴¹ emergence of COVID-19, testing supplies have repeatedly struggled to meet the demand during case surges associated with new COVID variants [\(6\)](#page-46-5).

 When COVID resources have fallen short of demand, experts and health agencies have rec- ommended the prioritization of testing supplies to the most severely symptomatic and vulnerable patients typically found in clinical health care settings, rather than to non-clinical cases associated with mildly or asymptomatic individuals and population monitoring programs [\(6,](#page-46-5) [7,](#page-46-6) [8\)](#page-46-7). This strat- egy seeks to maximize the utility of the few resources available by limiting the amount 'wasted' on individuals who are not infected, but in the process excludes the possibility of slowing disease spread by identifying and quarantining non-symptomatic infected individuals [\(9\)](#page-46-8). Achieving an ideal balance between clinical and non-clinical resource allocation is especially pertinent for a dis- ease like COVID-19, where undetected presymptomatic transmission caused by mismatched latent and incubation periods [\(10,](#page-47-0) [11\)](#page-47-1) as well as potentially large numbers of undetected totally asymp- $\frac{1}{53}$ tomatic spreaders $(12, 13, 14, 15)$ $(12, 13, 14, 15)$ $(12, 13, 14, 15)$ $(12, 13, 14, 15)$ $(12, 13, 14, 15)$ $(12, 13, 14, 15)$ $(12, 13, 14, 15)$ present significant barriers to controllability.

 Given the complexity of real-world disease dynamics with features like symptom-based test- ing and pre- and asymptomatic transmission, simplified compartmental mathematical models can provide powerful tools for analyzing and optimizing control strategies in the face of resource lim-itations. However, overly simplistic models can yield erroneous conclusions regarding real-world

 control strategies, so one must carefully balance model simplicity against the complex realistic elements most relevant to the problem at hand. Conventional compartmental COVID-19 control models are typically based on systems of ordinary differential equations (ODE's) [\(16,](#page-47-6) [17,](#page-47-7) [18,](#page-48-0) [19,](#page-48-1) [20,](#page-48-2) [21,](#page-48-3) [22,](#page-48-4) [23,](#page-48-5) [24,](#page-48-6) [25\)](#page-49-0). While ODE disease models provide a level of mathematical tractability, they necessitate the coupling of symptom status to specific model compartments, and this structural constraint can result in unnatural or unrealistic representations of symptom onset and presym- tomatic transmission with potential unintended consequences on model behavior and real-world interpretations. This limitation is especially problematic when modeling controls like clinical and non-clinical testing strategies that are directly tied to symptom status.

 ODE models for COVID-19 have generally addressed symptom onset and presymptomatic trans- mission by one of two broad schemes, both of which have their own drawbacks. One class of models simply ignores the potential for presymptomatic transmission by having infected individuals tran- sition from an exposed non-symptomatic non-infectious compartment to an infectious symptomatic compartment, often with an additional infection channel comprised of permanently asymptomatic infected individuals. Such models have been used to analyze testing, contact tracing, and quar- τ_3 antine control strategies [\(16,](#page-47-6) [17\)](#page-47-7), particularly in the context of limited resource constraints [\(18\)](#page-48-0), along with vaccination control [\(19\)](#page-48-1) and non-pharmaceutical interventions like masking and social distancing [\(20,](#page-48-2) [21\)](#page-48-3). Although useful as simple baseline examples, these models may overestimate the efficacy of symptom-based COVID-19 controls due to the absence of presymptomatic transmis- sion. A second more complicated class of ODE models includes a presymptomatic compartment where individuals are infectious but not yet symptomatic before transitioning to an infectious symptomatic compartment [\(22,](#page-48-4) [23,](#page-48-5) [24,](#page-48-6) [25\)](#page-49-0). This approach, while more realistic, presents chal- lenges when interpreting results for real world decision making via comparisons to the simpler class of models. Specifically, when multiple infectious stages are incorporated into an ordinary differ- ential equation model, the total infectious period is no longer exponentially distributed (as would occur for a single infectious stage), but is instead more similar to a gamma or Weibull distribu-⁸⁴ tion [\(26\)](#page-49-1), and such non-exponential distributions have been shown to be more difficult to control with identification-isolation strategies as compared to exponential distributions [\(27\)](#page-49-2). Thus, it is unclear to what degree differences in output between models with and without presymptomatic compartments are due to presymptomatic transmission itself or to the presence of non-exponential

 infectious periods, and this presents a barrier to interpreting model results for real-world decision making. Furthermore, when a totally asymptomatic infection channel is included, one must either add a fictitious presymptomatic compartment for this class or accept a major qualitative difference between the infectious period distributions of those who will never and those who will eventually show symptoms (exponential vs non-exponential). Either option may have important impacts on model behavior, yet to our knowledge, this issue may has not been explicitly addressed in the literature. Finally, the class of models with presymptomatic compartments can not be adapted to other diseases for which infectiousness peaks well after symptom onset (such as with the 2003 SARS coronavirus [\(28,](#page-49-3) [29\)](#page-49-4)) without significant changes to model structure, and this complicates any comparative mathematical analysis of diseases which are fundamentally similar to one another aside from changes in latent-incubation period mismatch. This deficit may be particularly prob- lematic for utilizing mathematical models to inform real-world control strategies for new emerging epidemics based on the lessons learned from COVID-19.

 We address these shortcomings by developing a partial integro differential equation model which utilizes the age of infection to decouple symptom status from specific model compartments. Our model is general in its ability to incorporate any latent, incubation, and infectious period distri- bution, regardless of shape or relative timings of means, and is utilized to analyze the original, delta, and omicron variants as well as a spectrum of other generically parameterized diseases all under a single lens. We incorporate a testing and quarantine control strategy which uses testing resources to identify infected individuals and remove them from the population while accounting for factors like contact tracing, limited population accessibility, and biases towards test-positive results. Our control assumes a fixed maximum testing capacity that must be allocated between clinical testing targeted at symptomatic individuals and non-clinical testing targeted at pre- and asymptomatic individuals. We analyze how controllability and optimal allocation strategies for reducing total infection size behave as functions of resource availability, testing quality, and dis- ease characteristics. In general, we find that most factors that reduce controllability also call for a smaller share of resources to be devoted to non-clinical testing in optimal strategies. However, although presymptomatic transmission is found to reduce controllability, whether or not it reduces the role of non-clinical testing in optimal strategies depends on a complicated relationship between latent-incubation offset, disease transmissibility, and latent period length. In particular, we find

 that diseases with presymptomatic transmission do not necessarily call for a increase in non-clinical testing resource allocation compared to diseases lacking presymptomatic transmission, despite the fact that intuition would deem non-clinical testing to be of greater importance due to its the po- tential to eliminate presymptomatic spreaders. Together, these results highlight how intuition for disease control strategies based on qualitative disease characteristics may fail and thus emphasize the need for mathematical modeling to prepare for and manage future epidemics.

$_{124}$ 2 Methods

 We extend the previous ordinary differential equation (ODE) SEIR testing and quarantine model of Calabrese and Demers [\(18\)](#page-48-0) to a system of integro-partial differential equations (IPDE) which explicitly incorporate the age of infection for infected classes. While our primary focus is COVID- 19, including the original, delta, and omicron variants, our system is general in its ability to account for any set of latent, incubation, and infectiousness periods.

2.1 Model outline

2.1.1 Uncontrolled transmission model

 We assume a homogeneously mixed system of N total susceptible, exposed, infectious, and recovered individuals. Exposed and infectious classes are partitioned into those who will remain permanently asymptomatic throughout the course of the infection and those who will eventually become symp- tomatic at some point before recovery. Here, we take "asymptomatic" to mean genuinely exhibiting no symptoms or exhibiting symptoms so minor that one would not typically consider themselves ill or seek medical attention, and "symptomatic" to mean exhibiting visually identifiable symptoms 138 with moderate to critical illness. Upon infection, initially susceptible individuals S will enter either 139 the exposed permanently asymptomatic class E_A or the exposed eventually symptomatic class E_Y 140 with probabilities f_A and f_Y , respectively (throughout this paper, we use the abbreviations PA and ES to denote permanently asymptomatic and eventually symptomatic individuals). While in an exposed class, individuals are infected but not yet infectious and are thus unable to transmit the disease to others. To account for the possibility of non-exponential waiting times between 144 infection sages, we continuously index exposed classes with the age of infection x. The number of

145 individuals in the exposed PA class at time t who have been infected between x and $x + dx$ units 146 of time is denoted $e_A(t, x)dx$ such that the total number of exposed PA individuals $E_A(t)$ is given ¹⁴⁷ by $E_A(t) = \int_0^\infty dx \, e_A(t, x)$. The age of infection-indexed exposed ES class $e_Y(t, x)$ is defined analo- 148 gously. PA and ES exposed individuals with infection age x transition to their respective infectious classes $a(t, x)$ and $y(t, x)$ at rate $\varepsilon(x)$. Infectious individuals enter into the recovered class R where ¹⁵⁰ they are no longer infectious and are assumed to attain permanent immunity at age of infection $_{151}$ dependent recovery rate $r(x)$. Although there is some evidence suggesting that ES and PA indi-¹⁵² viduals recover from COVID-19 at different rates, disease progression in asymptomatic individuals ¹⁵³ is poorly understood, and conflicting studies have shown faster, similar, and slower viral clearance 154 rates in asymptomatic versus symptomatic cases $(30, 31)$ $(30, 31)$ $(30, 31)$. For simplicity, we therefore take $r(x)$ ¹⁵⁵ to be equivalent for PA and ES infections. Likewise, we are aware of only one study suggesting ¹⁵⁶ different transitions rates from the exposed to infectious class for PA versus ES individuals [\(10\)](#page-47-0), ¹⁵⁷ but the corresponding average waiting times differ by only 5%, so we assume exposed to infectious ¹⁵⁸ transition rates to be independent of the eventual presence or lack of symptoms. The dynamical ¹⁵⁹ equations for the uncontrolled transmission model are as follows:

$$
\dot{S}(t) = -\lambda_A \beta \frac{A(t)}{N} S(t) - \lambda_Y \beta \frac{Y(t)}{N} S(t)
$$
\n(1a)

$$
\partial_t e_A(t, x) + \partial_x e_A(t, x) = -\varepsilon(x) e_A(t, x)
$$
\n(1b)

$$
e_A(t,0) = f_A\left(\lambda_A \beta \frac{A(t)}{N} S(t) + \lambda_Y \beta \frac{Y(t)}{N} S(t)\right)
$$
 (1c)

$$
\partial_t e_Y(t, x) + \partial_x e_Y(t, x) = -\varepsilon(x) e_Y(t, x)
$$
\n(1d)

$$
e_Y(t,0) = f_Y\left(\lambda_A \beta \frac{A(t)}{N} S(t) + \lambda_Y \beta \frac{Y(t)}{N} S(t)\right)
$$
 (1e)

$$
\partial_t a(t,x) + \partial_x a(t,x) = \varepsilon(x) e_A(t,x) - r(x) a(t,x) \tag{1f}
$$

$$
a(t,0) = 0 \tag{1g}
$$

$$
\partial_t y(t,x) + \partial_x y(t,x) = \varepsilon(x) e_Y(t,x) - r(x) y(t,x)
$$
\n(1h)

$$
y(t,0) = 0 \tag{1}
$$

$$
\dot{R}(t) = \int_0^\infty dx \left(r(x)a(t,x) + r(x)y(t,x) \right) \tag{1j}
$$

160

$$
E_A(t) = \int_0^\infty dx \, e_A(t, x), \quad E_Y(t) = \int_0^\infty dx \, e_Y(t, x), \tag{1k}
$$

$$
A(t) = \int_0^\infty dx \, a(t, x), \quad Y(t) = \int_0^\infty dx \, y(t, x).
$$

161 In the above equations, overdots denote ordinary derivatives with respect to time t, β denotes the ¹⁶² average number of contacts made per unit time by an individual, N is the total population size, and λ_A and λ_Y denote the transmission probability per susceptible-infectious contact for the PA and ¹⁶⁴ ES classes, respectively (for simplicity, we assume transmission probability to be independent of 165 the age of infection). The boundary terms $e_A(t, 0)$ and $e_Y(t, 0)$ denote the rates of newly generated 166 infections and thus represent to individuals with infection age $x = 0$. The boundary terms $a(t, 0)$ 167 and $y(t, 0)$ are zero due to the fact that every infected individual will spend at least some time in an ¹⁶⁸ exposed class before becoming infectious and will therefore never enter an infectious class with an 169 infection age $x = 0$. The integrals in Eq. [\(1k\)](#page-5-0) relate the total number of individuals in an infected ¹⁷⁰ class to the corresponding distribution over the age of infection.

 171 2.1.2 Symptom onset

 The model in Eq. [\(1\)](#page-5-1) makes no assumptions regarding the onset of symptoms in infected individ- uals. This modeling choice is based on the fact that the natural dynamics of disease transmission (absent interventions or controls explicitly correlated with symptom status) depend fundamentally on infectious states rather than symptom states. In our IPDE model, symptoms are an incidental background state which need not be represented by separate pre- and post-symptom onset com- partments for each infected compartment as would be required in an ordinary differential equation (ODE) model. We utilize the age of infection in the ES classes to the define the symptomatic 179 population $X_S(t)$ by the following integral:

$$
X_S(t) = \int_0^\infty dx \Big(P_e(x) e_Y(t, x) + P_y(x) y(t, x) \Big). \tag{2}
$$

180 The functions $P_e(x)$ and $P_y(x)$ denote the respective probabilities for exposed and infectious in- 181 dividuals to show symptoms by infection day x. These probabilities likewise determine the non-182 symptomatic infected population $X_N(t)$ as follows:

$$
X_N(t) = E_A(t) + A(t) + \int_0^\infty dx \Big((1 - P_e(x)) e_Y(t, x) + (1 - P_y(x)) y(t, x) \Big). \tag{3}
$$

¹⁸³ The non-symptomatic infected population is comprised of all PA infected individuals plus the ES ¹⁸⁴ infected individuals who are not yet showing symptoms.

185 In our simulations, we consider two assumptions for $P_e(x)$ and $P_y(x)$, "correlated symptoms" ¹⁸⁶ and "incubation symptoms:"

Correlated Symptoms:
$$
P_e(x) = 0, P_y(x) = 1.
$$
 (4)
Incubation Symptoms: $P_e(x) = P_y(x) = \int_0^x dx' f_I(x').$

 The correlated symptoms assumption defines symptom onset to occur in perfect correlation with infectiousness onset. Here, there is no possibility of pre-symptomatic transmission or pre-infectious symptom onset, and the symptomatic population is the entire ES infectious class. This assumption is equivalent to the symptom assumptions of our previous ODE testing and quarantine COVID-19 191 model in [\(18\)](#page-48-0). The incubation symptoms assumptions defines $P_e(x)$ and $P_y(x)$ to be the cumu-192 lative distribution function of an incubation period distribution $f_I(x)$. Here, $f_I(x)dx$ denotes the 193 probability for an ES individual to begin showing symptoms between age of infection x and $x+dx$. The flow diagram in Fig. [1](#page-8-0) summarizes the progression of infectious and symptomatic states in the uncontrolled transmission model.

Figure 1: Schematic indicating the flow of infectious and symptomatic states in our uncontrolled transmission model. Upon infection, susceptible individuals S move into either the permanently asymptomatic (PA) exposed class E_A or the eventually symptomatic (ES) exposed class E_Y with an initial age of infection $x = 0$. As individuals linger in the exposed classes, their ages of infection increase, and transitions to the PA infectious class A and ES infectious class Y occur at infection age dependent transition rate $\varepsilon(x)$ Infectious individuals then transition to the recovered class R at the infection-age-dependent transition rate $r(x)$. Symptom status appears as background state indicated by the red and green boxes. For ES exposed and infectious individuals with infection age x, a fraction $P_e(x)$ and $P_y(x)$, respectively, will be in the symptomatic state X_s , while the remaining fractions $1 - P_e(x)$ and $1 - P_y(x)$ will be in the non-symptomatic state X_N . The PA classes E_A and A remain in the non-symptomatic state X_N until recovery.

¹⁹⁶ 2.1.3 Testing and quarantine transmission model

 We adapt the resource allocation testing and quarantine control framework from the ODE model of [\(18\)](#page-48-0) to our IPDE disease model. Testing identifies and transfers infected individuals to a quarantine class Q where they remain isolated from contacts until recovery and are unable to generate new 200 transmissions. We assume a finite testing resource represented by the testing capacity C, defined as the maximum per capita number of tests able to be administered and processed per day. A frac- tion ρ of the testing capacity is allocated to non-clinical testing for identifying non-symptomatic 203 infected individuals, while the remaining fraction $1-\rho$ is allocated to clinical testing for identifying symptomatic infected individuals. Clinical testing is conducted only on individuals showing suffi- ciently severe visually identifiable symptoms, while non-clinical testing is accessible to the general public. The actual rate at which tests are administered and processed for the two testing categories ₂₀₇ is dependent on the *testing demand*, i.e. on the number of people eligible for and actively seeking testing. Here, we provide the functional forms of test administration and processing rates for clini- cal and non-clinical testing and sketch the reasoning behind their formulation. Further details are elucidated in [\(18\)](#page-48-0).

²¹¹ The average time required for a non-clinical test to be administered and processed for a single 212 individual is denoted τ_N such that the average administration and processing rate is given by $1/\tau_N$:

$$
\tau_N^{-1} = \begin{cases}\n0, & C = 0 \text{ or } \rho = 0 \\
\left[\tau + \kappa \frac{X_N(t) + (1-\eta)(S(t) + U(t))}{\rho CN}\right]^{-1}, & \text{otherwise}\n\end{cases}
$$
\n(5)

213 Non-clinical testing enters the disease model by transferring a fraction κ of the non-symptomatic infected population (either pre- or asymptomatic) to the quarantined class Q at rate τ_N^{-1} infected population (either pre- or asymptomatic) to the quarantined class Q at rate τ_N^{-1} . The case 215 $C = 0$ corresponds to no testing capacity and thus no control, while the case $\rho = 0$ corresponds to ²¹⁶ all resources being devoted to clinical testing which reduces the non-clinical testing rate to zero. 217 The quantity τ is the *intrinsic testing time*, defined as average time required for an individual get ²¹⁸ to a testing center, get tested, and receive results absent of delays or backlogs due to other patents. ²¹⁹ We take this value to be equal to one day. The testing demand for non-clinical testing is defined 220 as a fraction κ the non-symptomatic population $X_N(t)$ in Eq. [\(3\)](#page-6-0) as well as a fraction $\kappa(1-\eta)$ 221 of the uninfected population $S(t) + U(t)$. Here, $U(t)$ represents individuals who were previously

²²² infected and subsequently recovered without being tested and are thus unaware that they have ²²³ immunity (we assume recovered individuals who were tested and quarantined know that they ²²⁴ have immunity and therefore exclude themselves from future testing). The accessibility parameter $225 \kappa \in (0,1]$ represents the fraction of the total population open to and compliant with non-clinical 226 testing, and the *concentration parameter* $\eta \in [0, 1)$ represents the degree to which testing is focused ²²⁷ on or biased towards infected individuals. A purely random population monitoring program which 228 reaches all members of the population corresponds to $\kappa = 1$ and $\eta = 0$. Any factor that influences ²²⁹ a given test such that it will be more likely applied to an infected individual as compared to purely 230 random sampling will increase η . For example, those who suspect a recent disease exposure may ²³¹ be both more likely to seek testing and more likely to test positive compared a randomly selected 232 individual, and this influence will focus testing towards the X_N population and away from the $S+U$ ²³³ population. Likewise, a highly effective contact tracing program may result in a relatively large 234 value of η , but there may be many individuals unwilling to participate in government or health 235 agency efforts, so the corresponding value of κ may be relatively small. Generally, the differing ²³⁶ behavioral characteristics of individuals and differing testing policies of local governments unique ²³⁷ to differing regions will correspond to a variety of concentration and accessibility levels, so we will 238 analyze model results for a wide array of κ and η values. The analysis in [\(18\)](#page-48-0) shows that η can be estimated from data comparing test-positive to disease prevalence rates, and that $\eta = 0.95$ is an ²⁴⁰ upper bound on optimistically achievable values.

²⁴¹ The average time required for a clinical test to be administered and processed for a single 242 symptomatic individual is denoted τ_C such that the average administration and processing rate is 243 given by $1/\tau_C$:

$$
\tau_C^{-1} = \begin{cases} 0, & C = 0 \text{ or } \rho = 1 \\ \left[\tau + \frac{X_S(t)}{(1 - \rho)CN} \right]^{-1}, & \text{otherwise} \end{cases}
$$
(6)

²⁴⁴ Clinical testing enters the disease model by transferring symptomatic individuals to the quarantine class Q at rate τ_C^{-1} 245 class Q at rate τ_C^{-1} . The case $C = 0$ corresponds to no control, while the case $\rho = 1$ corresponds ²⁴⁶ to all resources being devoted to non-clinical testing which reduces the clinical testing rate to zero. ²⁴⁷ In contrast to non-clinical testing, clinical testing is assumed to have full concentration on and full

 accessibility to the target infected population, meaning that the testing demand is comprised only 249 of the symptomatic population X_S and includes no uninfected individuals. We base this on the assumption that all individuals in the ES classes who are currently showing symptoms are all ill enough to seek medical attentions (full advisability), and that due to the presence of strong visually identifiable symptoms and the lack of secondary diseases in our model, there is no chance of using a clinically allocated test on an uninfected individual (full concentration). In this sense, clinical testing acts as a verification tool, while non-clinical testing acts as an identification tool.

²⁵⁵ For both testing types, when testing demand is very low, tests are administered and processed 256 at maximum rates $\tau_C^{-1} \approx \tau^{-1}$ and $\tau_N^{-1} \approx \tau^{-1}$ per individual, and the total number of clinical ²⁵⁷ tests conducted per day grows linearly with the size of the symptomatic population. As demand increases, supply limitations and patient backlogs cause τ_C^{-1} \overline{C}^1 and τ_N^{-1} the increases, supply limitations and patient backlogs cause τ_C^{-1} and τ_N^{-1} to decrease towards zero, and 259 the total number of clinical and non-clinical tests conducted per day saturates to $(1 - \rho)CN$ and $260 \rho CN$, respectively, as testing demand approaches infinity. The full model equations with testing ²⁶¹ and quarantine control are given in Eq. [\(7\)](#page-11-0) and a corresponding flow diagram is given in Fig. [2.](#page-13-0) ²⁶² Table [1](#page-12-0) summarizes the definitions of all control-related parameters.

$$
\dot{S}(t) = -\lambda_A \beta \frac{A(t)}{N - Q(t)} S(t) - \lambda_Y \beta \frac{Y(t)}{N - Q(t)} S(t)
$$
\n(7a)

$$
\partial_t e_A(t, x) + \partial_x e_A(t, x) = -\varepsilon(x) e_A(t, x) - \kappa \tau_N^{-1} e_A(t, x)
$$
\n(7b)

$$
e_A(t,0) = f_A\left(\lambda_A \beta \frac{A(t)}{N - Q(t)} S(t) + \lambda_Y \beta \frac{Y(t)}{N - Q(t)} S(t)\right)
$$
(7c)

$$
\partial_t e_Y(t,x) + \partial_x e_Y(t,x) = -\varepsilon(x) e_Y(t,x) - \tau_C^{-1} P_e(x) e_Y(t,x)
$$
\n(7d)

$$
-\tau_N^{-1}\kappa\left(1 - P_e(x)\right)e_Y(t, x)
$$

\n
$$
e_Y(t, 0) = f_Y\left(\lambda_A \beta \frac{A(t)}{N - Q(t)} S(t) + \lambda_Y \beta \frac{Y(t)}{N - Q(t)} S(t)\right)
$$
\n(7e)

$$
\partial_t a(t,x) + \partial_x a(t,x) = \varepsilon(x) e_A(t,x) - r(x) a(t,x) - \tau_N^{-1} \kappa a(t,x) \tag{7f}
$$

$$
a(t,0) = 0 \tag{7g}
$$

$$
\partial_t y(t,x) + \partial_x y(t,x) = \varepsilon(x) e_Y(t,x) - r(x) y(t,x) - \tau_C^{-1} P_y(x) y(t,x)
$$
\n
$$
-\tau_N^{-1} \kappa (1 - P_y(x)) y(t,x)
$$
\n(7h)

$$
y(t,0) = 0 \tag{7i}
$$

$$
\partial_t q(t,x) + \partial_x q(t,x) = -r(x)q(t,x) + \tau_C^{-1} \Big[P_e(x)e_Y(t,x) + P_y(x)y(t,x) \Big] \tag{7j}
$$

$$
+\tau_N^{-1}\kappa \Big[e_A(t,x) + a(t,x) + (1 - P_e(x))e_Y(t,x) + (1 - P_y(x))y(t,x) \Big]
$$

$$
q(t,0) = 0 \tag{7k}
$$

$$
\dot{U}(t) = \int_0^\infty dx \left(r(x)a(t,x) + r(x)y(t,x) \right) \tag{71}
$$

$$
\dot{R}(t) = \int_0^\infty dx \left(r(x)a(t,x) + r(x)y(t,x) + r(x)q(t,x) \right) \tag{7m}
$$

263

$$
E_A(t) = \int_0^\infty dx e_A(t, x), \quad E_Y(t) = \int_0^\infty dx e_Y(t, x), \tag{7n}
$$

$$
A(t) = \int_0^\infty dx a(t, x), \quad Y(t) = \int_0^\infty dx y(t, x), \quad Q(t) = \int_0^\infty dx q(t, x).
$$

Table 1: Testing and quarantine control parameter definitions

264

Figure 2: Flow diagram for the testing and quarantine control model in Eq. [\(7\)](#page-11-0). The symptomatic population X_S and fraction κ of the non-symptomatic population X_N transition to the quarantine class Q by clinical and non-clinical testing, respectively, at rates τ_C^{-1} \overline{C}^1 and τ_N^{-1} \overline{N}^1 . Quarantined individuals transition to the recovered class R at age of infection dependent rate $r(x)$. The subset U of the recovered class represents individuals who were previously infected and subsequently recovered without testing and quarantine and are thus unaware that they have obtained immunity.

²⁶⁵ 2.1.4 Transition rates

266 The transition rates $\varepsilon(x)$ and $r(x)$ are determined by probability distributions for infection ages 267 at which transitions between disease states occur. Specifically, letting $f_{\varepsilon}(x)$ denote the probability 268 density for an infected individual to transition from exposed to infectious at infection age x , and 269 letting $f_r(x)$ denote the probability density for an infectious individual to transition to recovered 270 at infection age x, the corresponding transition rates are defined as follows:

$$
\varepsilon(x) = \frac{f_{\varepsilon}(x)}{1 - \int_0^x dx' f_{\varepsilon}(x')} \tag{8}
$$

$$
r(x) = \frac{f_r(x)}{1 - \int_0^x dx' f_r(x)}.
$$
\n(9)

 These transition rates represent conditional probability densities for an individual to transition to the next disease stage on infection day x given that they are still in the preceding disease stage up to day x. The probability densities for the infectious period duration and total infection duration, 274 denoted $f_{inf}(x)$ and $f_{tot}(x)$, respectively, can be written in terms of $f_{\varepsilon}(x)$ and $f_{r}(x)$ as follows:

$$
f_{inf}(x) = \int_0^\infty ds \, f_\varepsilon(s) \frac{f_r(x+s)}{1 - \int_0^s ds' \, f_r(s')},\tag{10}
$$

$$
f_{tot}(x) = \int_0^x ds \, f_{\varepsilon}(s) \frac{f_r(x)}{1 - \int_0^s ds' \, f_r(s')}.
$$
\n(11)

275 To clarify, $f_{tot}(x)dx$ represents the probability for an newly infected individual to remain infected for 276 a total duration between x and $x+dx$ days, $f_{inf}(x)dx$ represents the probability for that individual 277 to be infectious (i.e. contagious) for a total duration between x and $x + dx$ days over the course 278 of their infection, and $f_r(x)dx$ represents the probability for that individual to recover between 279 infection days x and $x+dx$ given that they have already entered into an infectious state. If $f_r(x)$ is 280 assumed to be an exponential distribution with mean $1/r$, $r(x)$ reduces to a constant $r(x) = r$ while 281 $f_{inf}(x)$ becomes equivalent to $f_r(x)$. Likewise, if $f_\varepsilon(x)$ is exponential with mean $1/\varepsilon$, $\varepsilon(x)$ reduces 282 to a constant $\varepsilon(x) = \varepsilon$. If both $f_r(x)$ and $f_{\varepsilon}(x)$ are exponential, $f_{tot}(x)$ becomes a two parameter 283 hypoexponential distribution with parameters ε and r. The exponential distribution assumptions ²⁸⁴ taken together with the correlated symptoms assumption in Sec. [2.1.2](#page-6-1) reduce the IPDE testing and ²⁸⁵ quarantine model in Eq. [\(7\)](#page-11-0) to the ODE testing and quarantine model in [\(18\)](#page-48-0).

²⁸⁶ 2.2 Distribution and parameter values

²⁸⁷ 2.2.1 COVID-19 variants

288 The distributions from which the transition rates $\varepsilon(x)$ and $r(x)$ are calculated, as well as the incu-²⁸⁹ bation period distribution, are based on epidemiological data for the original, delta, and omicron 290 COVID-19 variants. The incubation period distribution $f_I(x)$ is a widely studied quantity for the ²⁹¹ early strains of COVID-19 which has been variously fit to log-normal, gamma, or Weibull distri-292 butions [\(32,](#page-49-7) [33,](#page-50-0) [34,](#page-50-1) [35,](#page-50-2) [36,](#page-50-3) [37\)](#page-50-4). The latent period distribution $f_{\varepsilon}(x)$ and post-infectiousness onset 293 recovery day distribution $f_r(x)$ are comparatively less well studied. For the original COVID-19 294 strain and delta variant, we utilize the results of Xin et al. (10) and Kang et al. (11) , respectively, 295 which estimate both f_{ε} and f_I to be gamma distributions. We are aware of only one data-based ²⁹⁶ study estimating the incubation period distribution for the omicron variant, Tanaka et al. [\(38\)](#page-50-5), ²⁹⁷ which fits to a log-normal distribution with median 2.8 days. Other investigations estimating me-²⁹⁸ dians but not distributions have likewise obtained results approximately equal to 3 days $(39, 40)$ $(39, 40)$ $(39, 40)$. To 299 maintain consistency with the original and delta variants, we assume f_I for omicron to be gamma ³⁰⁰ distributed with mean and variance comparable to that of [\(38\)](#page-50-5). We are unaware of any existing ³⁰¹ estimates for the omicron variant's latent period distribution, so we assume a gamma distribution ³⁰² with mean 1.5 days shorter than that of the incubation period. For all variants, we are unaware 303 of any studies that directly estimate the post-infectiousness onset recovery day distribution $f_r(x)$. ³⁰⁴ However, viral culturing studies have consistently found live viral isolation to cease between 9 and 305 10 days post-symptom onset $(30, 31, 41)$ $(30, 31, 41)$ $(30, 31, 41)$ $(30, 31, 41)$ $(30, 31, 41)$. We therefore assume a gamma distribution for $f_r(x)$ with 306 mean $\langle f_r \rangle = \langle f_I \rangle + 9.5$ days for each variant, and we assume a scale parameter of 0.25 days to give ³⁰⁷ tight distributions with relatively small interquartile ranges as indicted in [\(41\)](#page-51-2).

³⁰⁸ To assess the impact of the PDE elements of our model relative to the corresponding ODE ³⁰⁹ model, we will compare simulation results under exponential and gamma distribution assumptions 310 for f_{ε} and f_r . Likewise, to assess the impact of pre-symptomatic transmission on disease controlla-³¹¹ bility, we will compare model results between the correlated symptoms and incubation symptoms 312 assumptions in Eq. [\(4\)](#page-7-0). The means $\langle f_{\varepsilon} \rangle$ are taken to be equivalent under the exponential and 313 gamma assumptions, while we set $\langle f_r \rangle = \langle f_I \rangle - \langle f_{\varepsilon} \rangle + 9.5$ days under the exponential assumption 314 as compared to $\langle f_r \rangle = \langle f_I \rangle + 9.5$ days under the gamma assumption. This difference ensures that

315 the mean infectious period duration $\langle f_{inf} \rangle$ and mean total infection time $\langle f_{tot} \rangle$ are essentially un-316 changed by the different assumptions on f_r . The means and standard deviations of f_ε, f_r , and f_I , 317 as well as that of the resultant distributions f_{inf} and f_{tot} , are given in Tables [2,](#page-17-0) [3,](#page-18-0) and [4](#page-18-1) for the 318 original, delta, and omicron COVID variants, respectively. Plots depicting the shapes of f_{ε}, f_r , 319 and f_I for the three variants are given in Fig. [3.](#page-19-0) For all variants and distribution assumptions, ³²⁰ the average infectious period is approximately 11 days while the average latent period is approx-³²¹ imately 1.5 days shorter than the average incubation period, thus indicating an average 1.5 day ³²² presymptomatic transmission window under the incubation symptoms assumption. The mean total ³²³ infection duration decreases from the original to delta to omicron variant.

 The remaining model parameters and values are summarized in Table [5.](#page-20-0) For all COVID vari-325 ants, the PA and ES population fractions, f_A and f_Y , respectively, are highly uncertain parameters, 326 as estimates based on both modeling and clinical data place f_A anywhere from less than 1% to 90% [\(12,](#page-47-2) [13,](#page-47-3) [14,](#page-47-4) [15\)](#page-47-5). Further, the value of f_A will depend precisely on our definition of the differ- ence between the moderate to critical symptoms exhibited by the ES class versus the mild to no symptoms exhibited by the PA class. Evidence has suggested the majority of COVID cases to be 330 mild [\(42,](#page-51-3) [43\)](#page-51-4), so based on these observations, we choose $f_A = 0.75$ and $f_Y = 0.25$. Likewise, the 331 relative values of the PA and ES transmission probabilities, λ_A and λ_Y , respectively, are highly uncertain. Various studies have show that non-symptomatic individuals are as, or less, infectious than symptomatic individuals [\(13,](#page-47-3) [14\)](#page-47-4), and that greater symptom severity correlates with higher viral loads [\(13,](#page-47-3) [14,](#page-47-4) [42\)](#page-51-3). Further, a study on the close contacts of index cases has suggested symp- tomatic individuals to be more infectious than asymptomatic individuals (44) . We therefore assume $\lambda_Y = 2\lambda_A$. To determine absolute values, we assume an average contact rate of $\beta = 4$ per day 337 and scale λ_A such that the model's uncontrolled basic reproduction number under the exponential α ₃₃₈ distribution assumptions (i.e. equivalent ODE model), denoted R_0^{un} , matches values taken from the literature (see the Supplementary Material section S1 and S2 for a derivation and discussion of the basic reproduction number). In other words, we define the following quantity:

$$
R_0^{un} = f_A \frac{\beta \lambda_A}{r} + (1 - f_A) \frac{\beta \lambda_Y}{r}, \qquad (12)
$$

341 and then choose λ_A such that the above expression matches values for the different COVID variants, 342 where the values of f_A and β are assumed, $1/r$ is equal to $\langle f_{inf} \rangle$ under the exponential distributions 343 assumptions in Tables [2,](#page-17-0) [3,](#page-18-0) or [4,](#page-18-1) and where we assume $\lambda_Y = 2\lambda_A$. Based on estimates of R_0 during the initial phases of the pandemic [\(45,](#page-52-1) [46,](#page-52-2) [47\)](#page-52-3), we set $R_0^{un} = 3.0$ for the original COVID variant. 345 Combining estimates from $(11, 48, 49)$ $(11, 48, 49)$ $(11, 48, 49)$ $(11, 48, 49)$ $(11, 48, 49)$, we set $R_0^{un} = 6.4$ for the delta variant. Based on $(49, 50)$ $(49, 50)$ $(49, 50)$, we s_{46} set $R_0^{un} = 9.5$ for the omicron variant. We note that changing exponential or gamma distribution 347 assumptions for f_r and f_ε have a negligible impact on actual model basic reproduction number (see $S₃₄₈$ Supplementary Material section S2), so R_0^{un} represents the uncontrolled basic reproduction number for all distribution and symptom onset assumptions.

Table 2: Original variant distributions based on Refs. [\(30,](#page-49-5) [31,](#page-49-6) [10,](#page-47-0) [41\)](#page-51-2). Simulations assume either exponential or gamma distributions for f_{ε} and f_r with means $\langle \ \rangle$ and standard deviations σ as indicated in units of days. Means and standard deviations for the resulting infectious period distribution f_{inf} and total infection duration distribution f_{tot} are likewise indicated. The incubation symptoms assumption utilizes a gamma distributed incubation period length f_I with indicated mean and standard deviation in units of days.

349

Table 3: Delta variant distributions based on Refs. [\(30,](#page-49-5) [31,](#page-49-6) [11,](#page-47-1) [41\)](#page-51-2). Meanings of quantities are as described in Table [2.](#page-17-0)

Table 4: Omicron variant distributions based on Refs. [\(30,](#page-49-5) [31,](#page-49-6) [38,](#page-50-5) [41\)](#page-51-2). Meanings of quantities are as described in Table [2](#page-17-0)

Figure 3: Latent period distributions $f_{\varepsilon}(x)$, incubation period distributions $f_{I}(x)$, and postinfectiousness onset recovery day distributions $f_r(x)$ as functions of the age of infection x for the original, delta, and omicron variants of COVID-19. Model simulations will consider combinations of exponential (dotted lines) and gamma (solid lines) distribution assumptions for f_{ε} and f_r , as well as an incubation period symptom onset assumption using a gamma distribution for f_I or a correlated symptom assumption where symptom onset coincides exactly with the onset of infectiousness.

³⁵⁰ 2.2.2 Generic diseases

³⁵¹ In addition to the COVID-19 variants, we consider a generic disease similar to the original variant 352 but with a variable offset between the mean incubation and latent period. Defining $z = \langle f_I \rangle - \langle f_{\varepsilon} \rangle$, 353 we consider both positive and negative z values. Positive z values represent diseases for which ³⁵⁴ symptom onset typically occurs after infectiousness onset, thus allowing for significant levels of pre-³⁵⁵ symptomatic transmission as occurs, for example, with the viruses SARS-CoV-2 and 2009 pandemic 356 influenza H1N1 [\(51,](#page-53-0) [52,](#page-53-1) [28\)](#page-49-3). Negative z values indicate viruses like SARS-CoV and MERS-CoV ³⁵⁷ for which symptom onset typically occurs well before infectiousness onset or peak infectivity, thus ³⁵⁸ making pre-symptomatic transmission insignificant or absent entirely [\(28,](#page-49-3) [29\)](#page-49-4). In all cases, we 359 assume fixed gamma distributions for f_{ε} and f_r similar to those of the original COVID-19 variant 360 and vary z by considering different gamma distributed incubation periods f_I . Assumed means and 361 standard deviations for f_{ε} , f_r , and f_I for the specific z values under consideration are given in 362 Table [6,](#page-21-0) and the distributions are pictured graphically in Fig. [4.](#page-21-1) Remaining model parameters are taken to be equivalent to those of COVID-19 in Table [5,](#page-20-0) where we will consider a variety of R_0^{un} 363 $_{364}$ and corresponding λ_A values.

Table 5: Model parameter definitions and numerical values used for COVID-19 variants.

		Offset $ z = -4.5 $ $ z = -3.0 $ $ z = -1.5 $ $ z = 0 $ $ z = 1.5 $ $ z = 3.0 $ $ z = 4.5 $					
$\langle f_I \rangle$ σ_I	1.50 1.22	3.00 1.91	4.50 2.27	6.00 2.83	7.50 2.83	9.00 2.83	10.50 2.83
		$\langle f_{\varepsilon} \rangle = 6.00, \sigma_{\varepsilon} = 2.83 \quad \langle f_r \rangle = 17.00, \sigma_r = 2.06$ $\langle f_{\text{inf}} \rangle = 11.02, \sigma_{\text{inf}} = 3.45 \quad \langle f_{\text{tot}} \rangle = 17.02, \sigma_{\text{tot}} = 2.06$					

Table 6: Gamma distribution parameters for generic diseases with different offsets between mean incubation and latent periods denoted by $z = \langle f_I \rangle - \langle f_{\varepsilon} \rangle$. Means $\langle \rangle$, standard deviations σ , and z values are given in units of days.

Figure 4: Latent period distribution $f_{\varepsilon}(x)$, incubation period distributions $f_I(x)$, and postinfectiousness onset recovery day distribution $f_r(x)$ as functions of the age of infection x for generic diseases with different offsets z between mean incubation and latent periods indicated in units of days.

³⁶⁵ 2.3 Numerical integration and optimization

³⁶⁶ We compute the discretized dynamical equations for the system [\(7\)](#page-11-0) using the upwind scheme for ³⁶⁷ non-linear partial integro-differential equations with integral boundary conditions [\(53\)](#page-53-2), and then ³⁶⁸ use the midpoint method to integrate the system forward in time. We assume initial infection 369 conditions $e_A(0, x)\Delta x = f_A$ and $e_Y(0, x)\Delta x = f_Y$ for $x \in [0, \Delta x]$, where $\Delta x = 1/6$ days is the 370 discretization length for the age of infection domain, and $e_A(0, x) = e_A(0, y) = 0$ for $x > \Delta x$. The 371 system is assumed otherwise to be initially completely susceptible such that $S(0) = N - 1$ and $372 \quad a(0,x) = y(0,x) = q(0,x) = R(0) = U(0) = 0$ for all x. Age of infection integrals are computed 373 using the trapezoid rule where we assume a finite domain with an upper bound $x_{max} = 80$ days 374 (the number of infected individuals who would otherwise recover after x_{max} is negligible for all 375 disease variants considered). We integrate the model equations from an initial time $t_0 = 0$ to final 376 time $t_f = 2$ years using a time step $\Delta t = 1/10$ days. When implementing testing and quarantine 377 control, we find optimal allocation strategies ρ for reducing the total infection size $S(t_0) - S(t_f)$ 378 under a variety of C, η , and κ values using the *fmincon* function in *Matlab R2021b*.

³⁷⁹ 3 Results

³⁸⁰ 3.1 Optimal total infection size reduction and disease controllability

 Figures [6](#page-26-0) and [7](#page-27-0) display total infection sizes under optimal resource allocation strategies as a func- tion of testing capacity for the different COVID variants as well as the generic disease with z and ³⁸³ R_0^{un} comparable to that of delta and omicron variants ($z = 1.5$ days and $R_0^{un} = 6.4$ or 9.5). Curve color and dashing pattern represent different combinations of assumptions regarding symptom onset 385 (incubation symptoms or correlated symptoms) and distributions for f_{ε} and f_{r} (gamma or expo- nential) as detailed by the legend in Fig. [5.](#page-25-0) Different plots represent different disease variants and 387 different choices for η and κ values. The presented results focus on two particular cases: "random 388 testing" ($\kappa = 1.00, \eta = 0$) and "realistic testing" ($\kappa = 0.85, \eta = 0.75$). Random testing represents a population-wide pure random sampling non-clinical testing program, while realistic testing repre- sents a non-clinical testing scenario more likely to be encountered in the real world, where contact tracing and natural biases result in increased testing of infected individuals but where some of the

 population is inaccessible or resistant to testing efforts. The case of no control is represented at 393 zero testing capacity $(C = 0)$. By definition, symptom onset assumptions and testing parameter 394 values have no influence on model outcomes at $C = 0$, but interestingly, we see that exponential 395 versus gamma distribution assumptions for f_ε and f_r have no meaningful impact on total infection 396 size at $C = 0$ even though model dynamics differ.

 397 Generally, as the testing capacity C increases, Figs. [6](#page-26-0) and 7 show that the total infection size decreases when resources are distributed optimally. In particular, complete disease eradication is possible at reasonably achievable testing capacities for a less infectious variant when non-clinical 400 testing can be effectively targeted at individuals who are actually infected (large η in Figs. [6b](#page-26-0) and $\frac{6d}{6d}$. However, if non-clinical testing does not target infected individuals (small η in Figs. [6a](#page-26-0) and [6c\)](#page-26-0), or if the variant is of greater infectiousness (Fig. [7\)](#page-27-0), eradication may not be achievable at the reduced testing capacities available during the initial phases of a novel disease outbreak. The accessibility κ has a smaller influence on reducing total infections compared to the concentration η , and disease eradication may possible even for smaller accessibility levels (Fig. [6d\)](#page-26-0). This result emphasizes the importance of implementing effective contact tracing programs for COVID-like dis-eases even if such programs can only reach a relatively small number of individuals.

 Together, Figs. [6](#page-26-0) and [7](#page-27-0) exemplify the influences of symptom onset assumptions, period distribu- tion assumptions, testing parameter values, and disease variant characteristics on disease control- lability. By controllability, we specifically mean the amount of testing capacity required to achieve a given reduction in total infection size. We consider a set 'A' of assumptions and parameters to be less controllable than another set 'B' if set 'A' requires a larger testing capacity to reduce total infection size to half, for example, of the uncontrolled value under optimal resource allocation strategies (see Supplementary Material section S4 for alternative but equivalent measures of con-trollability involving the basic reproduction number).

 Gamma versus exponential distribution assumptions for f_r have a profound effect on controlla- bility. Comparing a dashed curve (exponential) to a solid curve (gamma) of the same color in either Fig. [6a,](#page-26-0) [6b,](#page-26-0) or [7](#page-27-0) shows that the gamma assumption produces a large decrease in controllability 419 relative to the exponential assumption. On the other hand, the gamma assumption for f_{ε} increases controllability relative to the exponential assumption. This is seen in Fig. [6a,](#page-26-0) [6b,](#page-26-0) or [7](#page-27-0) by comparing a solid orange curve to a solid blue curve or a solid purple curve to a solid gold curve, and likewise

 for dashed curves. The effects of incubation symptom versus correlated symptom assumptions are exemplified by comparing a solid gold to solid blue curve or solid purple to solid orange curve, and likewise for dashed curves. Here, incubation symptom assumptions decrease controllability relative 425 to correlated symptom assumptions. Interestingly, for a given assumption on f_r , the decrease in controllability due to incubation symptoms is nullified to some extent by the increase in controlla-427 bility due to a gamma distributed f_ε such that solid (dashed) blue and purple curves can lie close to one another bounded by solid (dashed) red and gold curves. In other words, the IPDE specific assumptions for latent period length and symptom onset tend to counteract one another. However, the full IPDE model (solid purple curve) generally shows a significant reduction in controllability relative to the full ODE model (dashed blue curve).

432 The influences of the testing parameters η and κ on controllability are shown in Figs. [6c](#page-26-0) and [6d,](#page-26-0) where smaller values tend to decrease controllability. The influences of disease variant char- acteristics are seen by comparing Fig. [6b](#page-26-0) to the corresponding curves in all plots in Fig. [7.](#page-27-0) Here, the omicron COVID variant is significantly less controllable than the delta variant, and the delta variant is moderately less controllable than the original variant. These controllability reductions may be caused by either increases in transmissibility or decreases in the mean latent period length associated with each COVID variant, where $R_0^{un} = 3.0, 6.4,$ and 9.5 and $\langle f_\varepsilon \rangle = 5.48, 4.00,$ and 1.50 days for the original, delta, and omicron variants, respectively (the mean incubation-latent offsets α and mean infectious period lengths are approximately equal for all variants). The independent influences of transmissibility and latent period length can be deduced using the generic disease in 442 Figs. [7c](#page-27-0) and [7d.](#page-27-0) Here, the mean latent period $\langle f_\varepsilon \rangle = 6.00$ days is comparable to that of the original variant, and comparing Fig. [6b](#page-26-0) to Figs. [7c](#page-27-0) and [7d](#page-27-0) thus shows that increases in transmissibility alone cause decreases in controllability. Likewise, comparing Fig. [7a](#page-27-0) and [7b](#page-27-0) to Fig. [7c](#page-27-0) and Fig. [7d,](#page-27-0) 445 respectively, shows that decreases in $\langle f_{\varepsilon} \rangle$ alone cause decreases in controllability. A summary of all observed controllability reducing factors is given in Table [7.](#page-28-0)

Figure 5: Legend for interpreting curve color and style in Figs. [6,](#page-26-0) [7,](#page-27-0) [8,](#page-29-0) [9,](#page-30-0) and [10.](#page-33-0) Different colors represent different combinations of exponential and gamma distribution assumptions for f_{ε} along with different assumptions for correlated versus incubation symptom onset as indicated by the colored table. Dashed lines indicate the exponential distribution assumption for f_r while solid lines indicate the gamma distribution assumption. The model with all IPDE elements is given by a solid purple curve while the ODE equivalent model is given by a dashed blue curve.

(a) Original Variant: Variable Distribution and Symptom Assumptions

(c) Original Variant: Gamma Distribution and Incubation Symptom Assumptions

(b) Original Variant: Variable Distribution and Symptom Assumptions

Figure 6: Total infection sizes under optimal allocation strategies as a function of testing capacity for the original COVID variant under a variety of symptom onset, period distribution, and testing parameter assumptions. The meaning of curve color and dashed versus solid curves is given in Fig. [5.](#page-25-0) Note the changes in x-axis scale for each plot.

(a) Delta Variant: Variable Distribution and Symptom Assumptions

Variable Distribution and Symptom Assumptions

(b) Omicron Variant: Variable Distribution and Symptom Assumptions

Variable Distribution and Symptom Assumptions

Figure 7: Total infection sizes under optimal allocation strategies as a function of testing capacity for the delta and omicron COVID variants, as well a generic disease similar to COVID-19, under a variety of symptom onset, period distribution, and testing parameter assumptions. The meaning of curve color and dashed versus solid curves is given in Fig. [5.](#page-25-0) The generic disease assumes R_0^{un} values equal to those of the delta and omicron COVID variants with a mean latent period $\langle f_{\varepsilon} \rangle = 6.00$ days comparable to that of the original variant, and assumes a incubation-latent offset $z = 1.5$ days similar to all COVID variants. Note the changes in x-axis scale for each plot.

Controllability reducing factors for COVID-like diseases
f_r gamma distribution
f_{ε} exponential distribution
reduction in non-clinical concentration η
reduction in non-clinical accessibility κ
increase in overall transmissibility (i.e. R_0^{un})
reduction in mean latent period $\langle f_{\varepsilon} \rangle$
incubation symptoms

Table 7: List of controllability reducing factors observed in Figs. [6](#page-26-0) and [7](#page-27-0) for COVID variants and generically parameterized diseases with incubation-latent offset $z = 1.5$ days.

⁴⁴⁷ 3.2 Optimal allocation strategies

44[8](#page-29-0) Figures 8 and [9](#page-30-0) show the optimal resource allocation strategies ρ as a function of testing capacity ⁴⁴⁹ C corresponding to the total infection size reductions in Figs. [6](#page-26-0) and [7.](#page-27-0) Curve colors and styles are 450 interpreted analogously according to the legend in Fig. [5.](#page-25-0) The value $\rho = 0$ represents a clinical-451 testing only strategy while $\rho = 1$ represents a non-clinical testing only strategy, with intermediate ⁴⁵² values represent mixed clinical and non-clinical testing strategies. In all cases, we find that optimal ⁴⁵³ strategies call for clinical testing only at low testing capacities up to some strategy threshold ⁴⁵⁴ capacity C^{th} , beyond which optimal strategies become mixed. As testing capacity increases further 455 beyond C^{th} , optimal strategies call for greater and greater shares of resources to be devoted to ⁴⁵⁶ non-clinical testing.

⁴⁵⁷ The insets in each plot (except Fig. [8d\)](#page-29-0) zoom in on C^{th} values for the various distribution, 45[8](#page-29-0) symptom, testing parameter, and disease parameter assumptions. Figures 8 and [9](#page-30-0) show that all 459 of these factors except the non-clinical accessibility κ are important in determining C^{th} , while ⁴⁶⁰ Fig. [8d](#page-29-0) indicates that C^{th} is in fact independent of κ. This observation can be explained from ⁴⁶¹ our model equations, where the total rate of flow of infected individuals to the quarantine class due to non-clinical testing is given by τ_N^{-1} 462 due to non-clinical testing is given by $\tau_N^{-1} \kappa X_N(t)$. At the threshold C^{th} , the optimal fraction of 463 resources ρ devoted to nonclinical testing is only infinitesimally larger than zero, and Eq. [\(5\)](#page-9-0) implies τ_N^{-1} ⁴⁶⁴ $\tau_N^{-1} \kappa X_N(t) \approx \rho CNX_N(t)/\Big(X_N(t)+(1-\eta)(S(t)+U(t))\Big)$ for very small ρ . We thus conclude that the ⁴⁶⁵ rate at which individuals are quarantined by optimally allocated non-clinical testing is independent 466 of κ at testing capacities near C^{th} , and that κ effectively vanishes from the model equations under 467 optimal strategies at C^{th} .

(a) Original Variant: Variable Distribution and Symptom Assumptions

(c) Original Variant: Gamma Distribution and Incubation Symptom Assumptions

(d) Original Variant: Gamma Distribution and Incubation Symptom Assumptions

Figure 8: Optimal resource allocation strategies for the original COVID variant corresponding to the total infection sizes in Fig. [6.](#page-26-0) The value $\rho = 0$ corresponds to clinical-testing only strategy, $\rho = 1$ corresponds to non-clinical testing only, with intermediate values representing mixed strategies. Insets within plots (aside from Fig. [8d\)](#page-29-0) highlight strategy threshold testing capacity values C^{th} where strategies switch from clinical only to mixed. Note the changes in x-axis scale for each plot.

(a) Delta Variant: Variable Distribution and Symptom Assumptions

(c) Generic Disease $R_0^{un} = 6.4$, $z = 1.5$ days: Variable Distribution and Symptom Assumptions

(b) Omicron Variant: Variable Distribution and Symptom Assumptions

(d) Generic Disease $R_0^{un} = 9.5$, $z = 1.5$ days: Variable Distribution and Symptom Assumptions

Figure 9: Optimal resource allocation strategies for the delta and omicron COVID variants as well as comparable generic diseases with a longer mean incubation period $\langle f_{\varepsilon} \rangle = 6.0$ days. Optimal strategies correspond to the optimal total infection sizes in Fig. [7.](#page-27-0) The value $\rho = 0$ corresponds to clinical-testing only strategy, $\rho = 1$ corresponds to non-clinical testing only, with intermediate values representing mixed strategies. Insets within plots highlight strategy threshold testing capacity values C^{th} where strategies switch from clinical only to mixed. Note the changes in x-axis scale for each plot.

3.3 Controllability and the role of non-clinical testing

 Figures [6,](#page-26-0) [7,](#page-27-0) [8,](#page-29-0) and [9](#page-30-0) together depict the relationship between controllability and the role of non- clinical testing in optimal strategies. We say that the role of non-clinical testing is increased for set 'A' of distribution, symptom onset, testing parameter, and disease parameter assumptions relative to another set 'B' if the optimal ρ value at a given testing capacity for set 'A' is larger. Applying the same comparative analyses to Figs. [8](#page-29-0) and [9](#page-30-0) as was done for Figs. [6](#page-26-0) and [7](#page-27-0) in Sec. [3.1,](#page-22-0) we find that, except for the incubation symptoms assumption, all factors that reduce controllability in Table [7](#page-28-0) coincide with the factors that reduce the role of non-clinical testing. Thus there exists a strong relationship between controllability influencing factors and the role of non-clinical testing in optimal strategies.

 The relationship between non-clinical testing and symptom onset assumptions is more nuanced than for the other controllability reducing factors. Understanding this relationship is important for disease control, as symptom onset assumptions either incorporate (incubation symptoms) or disregard (correlated symptoms) the capacity for presymptomatic transmission associated with the incubation-latent period offset for COVID-19. In some cases (compare gold to blue or purple to orange curves in Figs. [8a](#page-29-0) and [8b\)](#page-29-0), incubation symptoms decrease the role of non-clinical testing relative to correlated symptoms, thus following the pattern of controllability reducing factors co- inciding with non-clinical testing reducing factors. In other cases (Fig. [9\)](#page-30-0), incubation symptoms increases the role of non-clinical testing for a large range of testing capacities above the strategy ϵ ⁴⁸⁷ thresholds C^{th} even though controllability is reduced. Of further complication, in these cases, there exist smaller ranges of larger testing capacities where the role of non-clinical testing is increased by the incubation symptoms assumption.

⁴⁹⁰ We utilize strategy testing capacity thresholds C^{th} to analyze the relationship between non- clinical testing and symptom onset assumptions. Specifically, in Figs. [8a](#page-29-0) and [8b,](#page-29-0) the reduced roles 492 of non-clinical testing under the incubation symptom assumptions correspond to larger C^{th} values in comparison to the correlated symptoms assumptions. Likewise, in Fig. [9,](#page-30-0) the enhanced roles of ⁴⁹⁴ non-clinical testing over large ranges of testing capacities correspond to smaller C^{th} for incubation ⁴⁹⁵ symptoms in comparison to correlated symptoms. Thus, increases and decreases in C^{th} due to symptom onset assumptions are simple indicators of decreases and increases, respectively, in the

 roles of non-clinical testing. To further simplify our analysis, we restrict our attention to the most 498 realistic model assumptions using gamma distributions for f_{ε} and f_r to compare incubation symp-toms (solid purple curves) to correlated symptoms (solid orange curves).

⁵⁰⁰ Numerically calculating C^{th} values for a spectrum of η values, we plot the results as curves in $\frac{1}{501}$ the (C, η) plane, where different curves represent different variant and symptom onset assumptions (Fig. [10\)](#page-33-0). For a given variant, if the correlated symptom curve (orange) falls to the left of the ϵ ₅₀₃ incubation symptom (purple) curve at a given η , then C^{th} is larger for incubation symptoms, thus ₅₀₄ implying that incubation symptoms reduce the role of non-clinical testing. Conversely, if the cor- related symptom curve falls to the right of the incubation symptoms curve, incubation symptoms enhance the role of non-clinical testing. Further, for each variant, there exists a threshold concen- η^{th} (indicated by black circles in Fig. [10\)](#page-33-0), above which the role of non-clinical testing is always enhanced, and below which it is always reduced, where threshold values decrease as variant strength increases. Thus, whether or not the presence of presymptomatic transmission warrants allocation of additional resources to non-clinical testing than would otherwise be optimal depends on both variant strength and the precision to which non-clinical tests can locate infected individ- uals: variants with greater infectiousness require less precision to justify additional resources for non-clinical testing.

 Figure [10](#page-33-0) is of additional value as a practical result for disease management officials when determining whether or not complicated resource allocation decisions need be considered. To see this, suppose that the available testing capacity C and an estimate for the concentration η of a 517 non-clinical testing program are known. Then, if the corresponding (C, η) value falls to the left of or below a variant curve in Fig. [10,](#page-33-0) the optimal strategy for that variant is clinical testing only, and 519 officials need not consider difficult choices in allocating resources. Otherwise, if the (C, η) value falls to the right of or above a variant curve, the optimal strategy is mixed clinical and non-clinical testing, and officials know that critical decisions must be made to ensure that resources are properly allocated.

Figure 10: Strategy threshold testing capacities at various concentration levels η for the different COVID variants. Curves represent (C, η) values where the strategy threshold capacity C^{th} occurs, assuming either incubation symptoms (purple) or correlated symptoms (orange) with gamma distributed f_r and f_ε . At (C, η) points above or to the right of a given curve, optimal strategies are mixed clinical and non-clinical for that variant and symptom assumption. At points below or to the left, optimal strategies are clinical only. Circles indicate points where C^{th} is equivalent for both symptom assumptions. At η values above a circle, incubation symptoms increases the role of non-clinical testing in optimal strategies for the corresponding variant. At η values below a circle, incubation symptoms reduce the role of non-clinical testing.

3.4 Variable incubation-latent offsets

 In Fig. [11,](#page-37-0) we plot optimal total infection sizes and corresponding optimal resource allocation szs strategies for the generic disease with $R_0^{un} = 3.0$ under a variety of incubation-latent offsets z. 526 Here, we consider only gamma distributions for f_r and f_ε , and we consider both incubation and correlated symptom assumptions (the offset z is irrelevant under correlated symptoms). The offset 528 z is found to have a strong influence on controllability (Figs. [11a](#page-37-0) and [11b\)](#page-37-0); as z increases from neg- ative to positive values, controllability decreases significantly. Thus, diseases for which symptom onset typically occurs before peak infectiousness are more easily controlled with symptom-based interventions compared to diseases for which symptom onset typically occurs after infectiousness onset (i.e. presymptomatic transmission). Further, relative to the correlated symptoms assump-533 tion, incubation symptoms are more controllable for $z < 0$ and less controllable for $z > 0$ (Figs. [11a](#page-37-0) and [11b\)](#page-37-0). This finding agrees with the notion that diseases for which symptoms precede signif- icant infectiousness are easier to control; if a model disregards the offset between symptom and $\frac{1}{536}$ infectiousness onset, it will underestimate controllability for diseases with $z < 0$ and overestimate controllability for diseases with $z > 0$. Thus, Table [1](#page-12-0) should be modified to state that incubation 538 symptoms are a controllability reducing factor only for diseases with $z > 0$, while correlated symp- toms are a controllability reducing factor for $z < 0$. This expanded list of controllability reducing $\frac{540}{40}$ factors is given in Table [8.](#page-38-0) For the case $z = 0$, controllability under incubation symptoms is close to (but not exactly equal to) controllability under correlated symptoms (Figs. [11a](#page-37-0) and [11b\)](#page-37-0). Appar- ently, when symptom and infectiousness onset occur together only on average rather than always together, controllability is very slightly reduced.

 As a function of testing capacity, optimal strategies for all z behave qualitatively similar to those of the COVID-19 variants; optimal strategies are clinical-only at low testing capacities and become mixed clinical and non-clinical beyond a threshold capacity C^{th} (Figs. [11c](#page-37-0) and [11d\)](#page-37-0). As with the COVID-19 variants, the relationships between symptom onset assumptions, controllabil- ity, and optimal allocation strategies are complicated for the generic disease. For random testing ⁵⁴⁹ (Fig. [11c\)](#page-37-0), the role of non-clinical testing decreases (as measured by increases in C^{th}) as z increases in the interval [−4.5, 1.5], thus following the trend of controllability reducing factors coinciding with $\frac{551}{251}$ non-clinical testing reducing factors. However, the role of non-clinical testing increases for $z = 4.5$

 552 days relative to $z = 1.5$ days even though controllability decreases. For realistic testing (Fig. [11d\)](#page-37-0), $\frac{1}{553}$ the role of non-clinical testing decreases progressively as z increases in the interval $[-4.5, 0]$, after which it progressively increases as z increases in $[0, 4.5]$. Of further complication, for larger R_0^{un} 554 ⁵⁵⁵ values (see Supplementary Material Figs. S10 and S11), the role of non-clinical testing can increase ⁵⁵⁶ progressively as z increases despite the progressive decrease in controllability.

⁵⁵⁷ The role of non-clinical testing for incubation symptoms relative to that of correlated symp-558 toms displays distinct behavior for $z < 0$ and $z \ge 0$. Specifically, for $z = -1.5$ days (green curve ⁵⁵⁹ in Figs. [11c](#page-37-0) and [11d\)](#page-37-0), the role of non-clinical testing is enhanced relative to correlated symptoms 560 at $\eta = 0$, but is reduced at $\eta = 0.85$. This behavior is counterintuitive; one would expect that $\frac{561}{10}$ if non-clinical testing is effective enough at low η to have an enhanced role in optimal strategies, 562 then it would also have an enhanced role at larger η , as increasing η would increase its efficacy 563 further. This is indeed the case for the COVID-19 variants that have a positive z approximately $_{564}$ equal to 1.50 days (Fig. [10\)](#page-33-0). For these variants, the role of non-clinical testing becomes enhanced ϵ_{565} relative to correlated symptoms at some threshold concentration η^{th} , and then remains enhanced 566 for all $\eta > \eta^{th}$. Figure [12](#page-39-0) presents the analog to Fig. [10](#page-33-0) for the generic disease for $R_0^{un} = 3.0$ ⁵⁶⁷ (see Supplementary Material Figs. $R_0^{un} = 6.4$ and $R_0^{un} = 9.5$). Here, we numerically calculate ⁵⁶⁸ the strategy threshold capacities C^{th} for a spectrum of η values for each z offset and the corre-569 lated symptoms assumptions, and then plot the results as curves in the (C, η) plane. For each z σ curve, there is a threshold concentration η^{th} where a crossing with the correlated symptoms curve ⁵⁷¹ occurs. $z \geq 0$ curves are to the right of the correlated symptoms curve for $\eta < \eta^{th}$ (indicating σ ₅₇₂ diminished non-clinical testing roles) and to the left for $\eta > \eta^{th}$ (indicating enhanced non-clinical testing roles). However, $z < 0$ curves are to the left of the correlated symptoms curve for $\eta < \eta^{th}$ ⁵⁷⁴ (indicating enhanced non-clinical testing roles) and to the right for $\eta > \eta^{th}$ (indicating diminished 575 non-clinical testing roles). We thus find major qualitative differences between $z > 0$ diseases (i.e. 576 those with presymptomatic transmission) and $z < 0$ diseases (i.e those with symptom onset before ⁵⁷⁷ infectiousness) in regards to the influence of realistic incubation and latent periods on optimal re-⁵⁷⁸ source allocation strategies relative to simpler models.

 579 From Figs. [10](#page-33-0) and [12](#page-39-0) (as well as the corresponding Figs. S12 and S13 in the Supplementary 580 Material), it is clear that threshold concentrations η^{th} depend on both the incubation-latent offset \mathcal{Z} and the overall transmissibility as measured by R_0^{un} , and may also depend on the mean latent

⁵⁸² period length. To visualize these influences, we find the thresholds η^{th} numerically for the $z \leq 0$ σ ₅₈₃ diseases as well as the COVID-19 variants, assuming a spectrum of R_0^{un} values for each model by ϵ_{584} changing the overall transmissibility. The results are plotted in Fig. [13](#page-40-0) as curves in the (R_0^{un}, η) ⁵⁸⁵ plane, where each curve represents η^{th} values for a different set of gamma distributed latent and 586 incubation periods taken from Tables [2,](#page-17-0) [3,](#page-18-0) [4,](#page-18-1) and [6,](#page-21-0) assuming gamma distributions for f_r . If a ⁵⁸⁷ disease management official is designing a testing resource allocation strategy to control a disease ⁵⁸⁸ for which they know the basic reproduction number and an estimate for their testing program's η reproduction, they can locate the corresponding point in Fig. [13.](#page-40-0) If their point falls above the ⁵⁹⁰ relevant incubation/latent period assumption curve, then due to presymptomatic transmission, op-⁵⁹¹ timal strategies will call for an increase in non-clinical testing resources relative to a comparable ⁵⁹² simpler disease for which infectiousness and symptoms always coincide. If their point falls below the ⁵⁹³ relevant incubation/latent period assumption curve, optimal strategies will call for a reduction in ⁵⁹⁴ non-clinical testing relative to a comparable simpler disease despite the presence of presymptomatic transmission. Generally, smaller R_0^{un} values require greater η to justify allocating extra resources ⁵⁹⁶ to non-clinical testing, thus corroborating our previous observation that diseases with greater in- $\frac{597}{2}$ fectiousness require less precise non-clinical testing programs (i.e smaller η) to justify allocating ⁵⁹⁸ additional resources to non-clinical testing due to presymptomatic transmission. We see further ⁵⁹⁹ that larger z diseases and diseases with shorter latent periods (compare the omicron curve to the ϵ_{600} $z = 1.50$ curve) likewise require less precision to justify increasing resources to non-clinical testing. ω In other words, the factors of larger R_0^{un} , larger z, and smaller latent period expand the parameter ⁶⁰² space for which non-clinical testing is enhanced in optimal strategies due to presymptomatic trans- ω ₆₀₃ mission. Note that as R_0^{un} falls below 2.0, enhanced non-clinical testing is never justified. Thus, ⁶⁰⁴ diseases with sufficiently low infectiousness do not warrant additional non-clinical testing resources, ⁶⁰⁵ even if presymptomatic transmission may be significant.

(a) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets

(c) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets

(b) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets

(d) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets

Figure 11: Optimal total infection sizes and corresponding optimal resource allocation strategies for the generic disease with $R_0^{un} = 3.0$, assuming gamma distributions for f_ε and f_r . Curve colors represent different offsets $z = \langle f_I \rangle - \langle f_{\varepsilon} \rangle$ between mean incubation and latent periods as indicated by the legend in Fig. [11a](#page-37-0) (measured in units of days). Black dashed curves represent the correlated symptoms assumption where z values are irrelevant. Insets in Figs. [11c](#page-37-0) and [11d](#page-37-0) zoom in on strategy threshold testing capacities C^{th} where optimal strategies switch from clinical only to mixed clinical and non-clinical.

Controllability reducing factors				
f_r gamma distribution				
f_{ε} exponential distribution				
reduction in non-clinical concentration η				
reduction in non-clinical accessibility κ				
increase in overall transmissibility (i.e. R_0^{un})				
reduction in mean latent period $\langle f_{\varepsilon} \rangle$				
incubation symptoms when $z > 0$				
correlated symptoms when $z < 0$				

Table 8: Expanded list of controllability reducing factors for both $z > 0$ and $z < 0$ diseases as observed in Figs. [6,](#page-26-0) [7,](#page-27-0) and [11.](#page-37-0)

Figure 12: Strategy threshold testing capacities at various concentration levels η for the generic disease with $R_0^{un} = 3.0$. Curves represent (C, η) values where the strategy threshold capacity C^{th} occurs, assuming either incubation symptoms (colored curves) or correlated symptoms (black dashed curve) with gamma distributed f_r and f_ε . Colors represents different off sets z between the mean incubation and mean latent period, with values in the legend given in units of days. At (C, η) points above or to the right of a given curve, optimal strategies are mixed clinical and non-clinical for that z value or symptom assumption. At points below or to the left, optimal strategies are clinical only. The η value for which a colored curve crosses the black curve represents a threshold η^{th} for which the role of non-clinical testing switches between enhanced and diminished compared to the correlated symptoms assumption.

Figure 13: Curves depicting threshold concentrations η^{th} as a function of the uncontrolled basic reproduction number for gamma distributed latent and incubation period associated with the COVID-19 variants and our generic diseases, where f_r is assumed to be gamma distributed. Each curve represents a different latent/incubation period set that has a particular incubation-latent offset z denoted in the legend in units of days. The legend specifies the COVID variants along with their z offsets, and the generic disease indicated by only their z offsets. The actual R_0^{un} values for the COVID variants are indicated by makers on the plot. Points above a given curve represent the parameter space over which presymptomatic transmission justifies increasing resources to nonclinical testing for a disease with the corresponding latent and incubation periods. For points below a curve, presymptomatic transmission does not justify increasing non-clinical testing resources in optimal strategies.

4 Discussion

4.1 Curbing epidemics under resource limitations

 The results of our work build a robust mathematical justification for the optimality of the test- ing strategies adopted by real-world disease management planners during the early phases of the COVID-19 pandemic. Namely, when testing resources are in short supply, they should be reserved for the most symptomatic and critically ill patients $(6, 7, 8)$ $(6, 7, 8)$ $(6, 7, 8)$ $(6, 7, 8)$ $(6, 7, 8)$. Although these policies may have been adopted to prevent mortality, we have found that they are also good policies for suppressing an epidemic. More generally, our work shows that such policies are optimal for a broad range of disease characteristics and non-clinical testing program characteristics. Diseases with longer or shorter latent periods, stronger or weaker transmissibility, presymptomatic transmission or symp- tom onset before infectiousness or correlated symptom-infectiousness onset, and exponential or gamma period distributions all call for qualitatively similar policies as a function of testing ca- ϵ ₆₁₈ pacity; optimal protocols call for clinical-only testing at testing capacities below a threshold C^{th} , and call for mixed clinical and non-clinical strategies at greater testing capacities. Interestingly, in a previous work [\(18\)](#page-48-0) where we analyzed optimally reducing the epidemic peak height (rather than total infection size) using the reduced and simplified ODE counterpart of our model here, we observed the same threshold behavior separating testing capacity regions between optimal clinical- only and mixed strategies. Thus, the threshold behavior appears to be a general feature of optimal allocation strategies under limited testing resources.

 Figures [6,](#page-26-0) [7,](#page-27-0) and [11](#page-37-0) depicting optimal total infection size for "realistic" and "random" non- clinical testing programs illuminate the feasibility or infeasibility of curbing a novel disease outbreak 627 with a testing and quarantine program. Random testing $(\eta = 0)$ is unlikely to be successful at the low testing capacities expected at the initial stages of a novel disease outbreak as production of newly developed tests falls well behind demand, even if the entire population is accessible and 630 amenable to the limited number of tests available ($\kappa = 1$). However, significant disease suppression 631 is possible at larger concentrations η even if the overall accessibility κ is small. This result stresses the importance of early implementation of effective contact tracing and public outreach programs encouraging individuals with suspected or probable recent transmission to seek testing, even if significant portions of the population are not open or accessible to such efforts. Importantly, this

 conclusion holds for the spectrum of model assumptions and disease characteristics analyzed in this paper.

4.2 Influence of model assumptions on controllability

 Throughout this work, we have identified a number of disease characteristics and model assumptions that influence predictions of controllability. Model assumptions regarding latent period, incubation period, and recovery day distributions as well as incubation-latent offsets are critically important, as we have found that the exponential distribution and correlated symptom assumptions in the equivalent ODE model can severely overestimate controllability relative to the full IPDE model 643 for the COVID-19 variants. The gamma distribution assumptions for f_{ε} , f_I , and f_T used in the full IPDE model are supported by epidemiological data and are far more realistic than ODE as- sumptions, so the reduced controllability exhibited by our model is a closer reflection of reality. Our model's ability to decouple symptom onset from disease compartments plays a key role in its capacity to simultaneously incorporate realistic latent and incubation period distributions.

 A major contributing factor to reduced controllability in the full IPDE model is the gamma 649 period distribution for f_r . This observation accords with previous models with identification + isola- tion/quarantine controls, where it was observed that an exponentially distributed infectious period can significantly overestimate controllability relative to a gamma distribution [\(27\)](#page-49-2). In essence, quarantining is more effective under the exponential assumption due to its ability to significantly reduce the infectious period length of individuals in the long tail of the distribution (see Fig. [3\)](#page-19-0). Likewise, under the exponential assumption, significantly larger numbers individuals recover nat- urally within the first few days of infectiousness onset in comparison to the gamma assumption, so delays in testing due to low capacity are irrelevant in these cases and are thus less detrimental to controllability. Conversely, for the latent period distribution, a gamma distribution assumption increases controllability relative to the exponential assumption (although to a lesser degree than ϵ_{659} that with which a gamma f_r reduces controllability) for reasons analogous to those of infectious period. Namely, under the exponential assumption, much larger numbers of individuals rapidly transition from exposed to infectious in comparison to the gamma distribution, so there is less time to locate and remove new infections before they begin generating new transmissions, and delays in identifying and quarantining infections due to supply limitations are thus more detrimental. On a

 ϵ_{664} more basic level, although gamma distributions for f_{ε} and f_r have no noticeable effect on total in- fection size under no control, they flatten/delay and sharpen/accelerate the uncontrolled epidemic peak, respectively, as compared to exponential distributions (see the Supplementary Material sec- tion S3). Intuitively, a disease that peaks earlier and to a greater degree on its on volition will be more difficult to control.

 Symptom onset assumptions based on the age-of-infection can reduce or increase controllability ϵ_{670} depending on the incubation-latent offset z, as controllability generally decreases as z increases. Under correlated symptoms, active spreaders in the ES class always show symptoms and are thus always targeted with efficacious clinical testing. Under incubation symptoms, however, positive z values imply presymptomatic transmissions, meaning that some of the active spreaders can only be targeted with non-clinical testing which is subject to delays due to resources being wasted on uninfected individuals. These delays become more detrimental as the presymptomatic transmission window becomes larger, so controllability tends to decrease as z increases. For negative z, however, some individuals become symptomatic while still in the exposed class, so efficacious clinical testing can be used to remove infected individuals with minimal delay before they can begin generating ϵ_{679} new transmissions. This is impossible under correlated symptoms or positive z values. The oppor- $\frac{680}{100}$ tunity for clinical testing to remove preinfectious individuals increases as z grows in the negative direction, and controllability consequently increases. Notably, the increase in controllability can be ϵ_{682} significant for a negative z disease compared to a positive z disease. This observation may explain 683 why the 2003 SARS outbreak (negative z disease) was far easier to control than the COVID-19 $_{684}$ pandemic (positive z disease) (54) .

 The remaining controllability reducing factors are straightforwardly explained. Namely, a more ϵ_{686} transmissible disease (i.e. one with a larger R_0^{un}) is inherently more difficult to control than a less transmissible disease, and the larger number of secondary infections generated by an individual can be detrimental to control when limited resources force delays in testing and quarantine. Likewise, shorter latent periods leave less time to locate infected individuals before they begin generating transmissions, so testing and quarantine delays become more costly. These factors together help ϵ_{691} explain why the omicron variant has been particularly challenging to control $(49, 55)$ $(49, 55)$ $(49, 55)$. The large R_0^{un} value is an oft emphasized contributing factor, but the short latent period relative to other variants can be just as important. Explicitly, comparing the generic disease (mean latent period 6

 days) to the omicron variant (mean latent period 1.5 days) in Fig. [7](#page-27-0) shows that omicron is roughly ⁶⁹⁵ half as controllable despite both diseases having the same R_0^{un} .

4.3 Controllability, symptom onset, and the role of non-clinical testing

 Our results across all model assumptions demonstrate a consistent clear relationship between non- clinical testing and controllability reducing factors unrelated to symptom onset assumptions: factors that reduce controllability also reduce the role of non-clinical testing in optimal strategies. We hy- pothesize that this relationship arises because wasted or inefficiently used resources are of greater detriment in a less controllable system. That is, when a disease is considered less controllable, fail- ure to utilize a quantity of testing capacity to identify and isolate infected individuals will result in a greater number of additional infections in comparison to a more controllable disease. With non- clinical testing, the beneficial impact of identifying removing non-symptomatic infected individuals is counterbalanced by the negative impact of potentially wasting tests on uninfected individuals, and the negative impact becomes more prominent as the disease becomes less controllable. Thus, optimal strategies place more emphasis on clinical testing which is guaranteed to be utilized to iden- tify and isolate an infected individual. However, for sufficiently large testing capacity, resources are plentiful enough such that wasting a test on an uninfected individual does not significantly delay or inhibit identification of infected individuals, so the role of non-clinical testing can be prominent in a less controllable disease, although still slightly diminished in comparison to a more controllable disease. Thus, the observed relationship between the role of non-clinical testing and controllability is closely tied to the resource limitation aspects of model.

 In contrast to factors unrelated to symptom onset, the relationship symptom onset assumptions and non-clinical testing is unclear. One one hand, one might expect that for a negative z disease like COVID-19, realistically modeling the incubation-latent offset will increase the role of of non-clinical testing in comparison to a model making the simpler correlated symptom assumption due to the ability of non-clinical testing to capture presymptomatic spreaders. On the other hand, since the $_{719}$ latent incubation offset decreases controllability for a negative z disease, one might expect the role of non-clinical testing to be diminished due to the reasoning given in the preceding paragraph. We found that neither of these hypotheses are generally correct for guiding optimal strategies based on the results of simple ODE models. Instead, we found that age-of-infection modeling, and in

 particular, the details of the temporal offset between the incubation and latent periods, was critical to understanding disease progression, controllability, and optimal strategies for resource allocation. Our results show that optimal policies for resource allocation depend on a complicated (often non-intuitive) interplay between incubation-latent offset, disease strength, and other characteris- tics like latent period length (Figs. [11,](#page-37-0) [12,](#page-39-0) [13](#page-40-0) and the corresponding Figs. S10, S11, S12, S13 in the Supplementary Material). This is a critical observation because real-world public policies and attitudes towards a novel diseases are typically based on what has been successful for previous diseases combined with basic intuition for the broad differences between the novel disease and pre- vious diseases. For example, 2003 SARS has no presymptomatic transmission while COVID-19 has significant presymptomatic transmission, so one might intuitively expect that a successful strat- egy for controlling 2003 SARS should be adapted for COVID-19 by allocating more resources to non-clinical testing to capture presymptomatic spreaders, but this is not at all the case accord- ing to our results. Our work shows that this intuition-based approach to public policy can fail, and thus highlights the importance of mathematical modeling in helping to guide disease man- agement. In particular, it is important to establish modeling frameworks where different diseases can be examined comparatively under the same lens to more closely mimic the way diseases are compared in the real world. Utilizing the age-of-infection to decouple symptom status from specific model compartments is the crucial element for allowing such comparisons in our model. Future models may build upon these ideas to incorporate not only the age-of-infection, but also the age- of-infectiousness to model additional realistic features like partial correlations between incubation, latent, and infectious period lengths as well as time-varying infectivity levels dependent on the time since infectiousness or symptom onset.

Acknowledgments

 This work was funded by the Center of Advanced Systems Understanding (CASUS) which is fi- nanced by Germanys Federal Ministry of Education and Research (BMBF) and by the Saxon Ministry for Science, Culture and Tourism (SMWK) with tax funds on the basis of the budget approved by the Saxon State Parliament.

References

- [1] World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020, 2020. [cited 2022 October 24]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020.
- [2] World Health Organization. WHO COVID-19 Dashboard, 2020. [cited 2022 October 24]. Available from: https://covid19.who.int/.
- [3] Antoine Mandel and Vipin Veetil. The economic cost of COVID lLockdowns: An out- of-eEquilibrium analysis. Econ Disaster Clim Chang, 4:431–451, 2020. doi: 10.1007/ s41885-020-00066-z.
- [4] Adam Rose. COVID-19 economic impacts in perspective: A comparison to recent U.S. disas- τ_{61} ters. Int J Disaster Risk Reduct, 60:102317, June 2021. doi: 10.1016/j.ijdrr.2021.102317.
- [5] Eva Clark, Elizabeth Y Chiao, and E Susan Amirian. Why contact tracing efforts have failed to curb coronavirus disease 2019 (COVID-19) transmission in much of the United States. Clin Infect Dis, 72:e415–e419, 2021. doi: 10.1093/cid/ciaa1155.
- [6] E. Susan Amirian. Prioritizing COVID-19 test utilization during supply shortages in the late p_{166} phase pandemic. *J Public Health Policy*, 43:320–324, 2022. doi: 10.1057/s41271-022-00348-8.
- [7] Centers for Disease Control and Prevention. Investigating a COVID-19 case, 2022. [cited 2022 October 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/investigating-covid-19-case.html.
- [8] World Health Organization. Public health surveillance for COVID-19: Interim guidance, 2022. [cited 2022 October 24]. Available from: https://www.who.int/publications/i/item/WHO-

2019-nCoV-SurveillanceGuidance-2022.2.

 [9] William V. Padula. Why only test symptomatic patients? Consider random screen- ing for COVID-19. Appl Health Econ Health Policy, 18:333–334, 2020. doi: 10.1007/ s40258-020-00579-4.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.11.06.22281984;](https://doi.org/10.1101/2022.11.06.22281984) this version posted February 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has grante

 [11] Min Kang, Hualei Xin, Jun Yuan, Sheikh Taslim Ali, Zimian Liang, Jiayi Zhang, Ting Hu, Eric HY Lau, Yingtao Zhang, Meng Zhang, Benjamin J Cowling, Yan Li, and Peng Wu. Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta vari- ant infections in Guangdong, China, May to June 2021. Eurosurveillance, 27, 2022. doi: 10.2807/1560-7917.ES.2022.27.10.2100815.

 [12] Nathan W. Furukawa, John T. Brooks, and Jeremy Sobel. Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic. Emerg Infect Dis, 26:e201595, 2020. doi: 10.3201/eid2607.201595.

- [13] Kieran A. Walsh, Karen Jordan, Barbara Clyne, Daniela Rohde, Linda Drummond, Paula Byrne, Susan Ahern, Paul G. Carty, Kirsty K. O'Brien, Eamon O'Murchu, Michelle O'Neill, Susan M. Smith, Mirn Ryan, and Patricia Harrington. SARS-CoV-2 detection, viral load and $\frac{790}{200}$ infectivity over the course of an infection. *J Infect*, 81:357–371, 2020. doi: 10.1016/j.jinf.2020. 06.067.
- [14] Arabella Widders, Alex Broom, and Jennifer Broom. SARS-CoV-2: The viral shedding vs $\frac{793}{793}$ infectivity dilemma. *Infect Dis Health*, 25:210–215, 2020. doi: 10.1016/j.idh.2020.05.002.
- [15] Qiuyue Ma, Jue Liu, Qiao Liu, Liangyu Kang, Runqing Liu, Wenzhan Jing, Yu Wu, and Min Liu. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: A systematic review and meta-analysis. JAMA Netw Open, 4:e2137257, 2021. doi: 10.1001/jamanetworkopen.2021.37257.
- [16] Amin Yousefpour, Hadi Jahanshahi, and Stelios Bekiros. Optimal policies for control of the novel coronavirus disease (COVID-19) outbreak. Chaos Solitons Fractals, 136:109883, 2020. doi: 10.1016/j.chaos.2020.109883.
- [17] Lautaro Vassallo, Ignacio A. Perez, Lucila G. Alvarez-Zuzek, Julin Amaya, Marcos F. Torres, Lucas D. Valdez, Cristian E. La Rocca, and Lidia A. Braunstein. An epidemic model for

- COVID-19 transmission in Argentina: Exploration of the alternating quarantine and massive ⁸⁰⁴ testing strategies. Math Biosci, 346:108664, 2022. doi: 10.1016/j.mbs.2021.108664.
- [18] Justin M. Calabrese and Jeffery Demers. How optimal allocation of limited testing capacity 806 changes epidemic dynamics. J Theor Biol, 538:111017, 2022. doi: 10.1016/j.jtbi.2022.1110173.
- [19] Alberto Olivares and Ernesto Staffetti. Optimal control-based vaccination and testing strategies for COVID-19. Comput Methods Programs Biomede, 211:106411, 2021. doi: 10.1016/j.cmpb.2021.106411.
- [20] Steffen E. Eikenberry, Marina Mancuso, Enahoro Iboi, Tin Phan, Keenan Eikenberry, Yang Kuang, Eric Kostelich, and Abba B. Gumel. To mask or not to mask: Modeling the potential ⁸¹² for face mask use by the general public to curtail the COVID-19 pandemic. *Infect Dis Model*, 5:293–308, 2020. doi: 10.1016/j.idm.2020.04.001.
- [21] Kristina P. Vatcheva, Josef Sifuentes, Tamer Oraby, Jose Campo Maldonado, Timothy Huber, and Mara Cristina Villalobos. Social distancing and testing as optimal strategies against the spread of COVID-19 in the Rio Grande Valley of Texas. Infect Dis Model, 6:729–742, 2021. doi: 10.1016/j.idm.2021.04.004.
- [22] Calistus N. Ngonghala, Enahoro A. Iboi, and Abba B. Gumel. Could masks curtail the post- lockdown resurgence of COVID-19 in the US? Mathl Biosci, 329:108452, 2020. doi: 10.1016/ j.mbs.2020.108452.
- [23] Colin J. Worby and Hsiao-Han Chang. Face mask use in the general population and optimal resource allocation during the COVID-19 pandemic. Nat Commun, 11:4049, 2020. doi: 10. 1038/s41467-020-17922-x.
- [24] Sarah F. Poole, Jessica Gronsbell, Dale Winter, Stefanie Nickels, Roie Levy, Bin Fu, Maximilien Burq, Sohrab Saeb, Matthew D. Edwards, Michael K. Behr, Vignesh Kumaresan, Alexander R. Macalalad, Sneh Shah, Michelle Prevost, Nigel Snoad, Michael P. Brenner, Lance J. Myers, Paul Varghese, Robert M. Califf, Vindell Washington, Vivian S. Lee, and Menachem Fromer. 828 A holistic approach for suppression of COVID-19 spread in workplaces and universities. PLoS $\emph{829}$ One, 16:e0254798, 2021. doi: 10.1371/journal.pone.0254798.

 [25] Joshua Kiddy K. Asamoah, Zhen Jin, Gui-Quan Sun, Baba Seidu, Ernest Yankson, Afeez Abidemi, F.T. Oduro, Stephen E. Moore, and Eric Okyere. Sensitivity assessment and op- timal economic evaluation of a new COVID-19 compartmental epidemic model with control interventions. Chaos Soliton Fractal, 146:110885, 2021. doi: 10.1016/j.chaos.2021.110885.

[26] Paul J. Hurtado and Adam S. Kirosingh. Generalizations of the Linear Chain Trick: incorpo-

 $\frac{835}{100}$ rating more flexible dwell time distributions into mean field ODE models. *J Math Biol*, 79(5):

1831–1883, 2019. doi: 10.1007/s00285-019-01412-w.

837 [27] Helen J Wearing, Pejman Rohani, and Matt J Keeling. Appropriate models for the manage-838 ment of infectious diseases. PLoS Med, 2:e174, 2005. doi: 10.1371/journal.pmed.0020174.

 [28] Zhonglan Wu, David Harrich, Zhongyang Li, Dongsheng Hu, and Dongsheng Li. The unique features of SARSCoV2 transmission: Comparison with SARSCoV, MERSCoV and 2009 H1N1 $_{841}$ pandemic influenza virus. Rev Med Virol, 31:e2171, 2021. doi: 10.1002/rmv.2171.

 [29] Guang Zeng, Shu-Yun Xie, Qin Li, and Jian-Ming Ou. Infectivity of severe acute respiratory 843 syndrome during its incubation period. *Biomed Environ Sci*, 22:502–510, 2009. doi: 10.1016/ 844 S0895-3988(10)60008-6.

 [30] Andrew William Byrne, David McEvoy, Aine B Collins, Kevin Hunt, Miriam Casey, Ann Bar- ber, Francis Butler, John Griffin, Elizabeth A Lane, Conor McAloon, Kirsty O'Brien, Patrick Wall, Kieran A Walsh, and Simon J More. Inferred duration of infectious period of SARS-CoV- 2: Rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open, 10:e039856, 2020. doi: 10.1136/bmjopen-2020-039856.

 [31] Muge Cevik, Matthew Tate, Ollie Lloyd, Alberto Enrico Maraolo, Jenna Schafers, and Antonia Ho. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shed- ding, and infectiousness: A systematic review and meta-analysis. Lancet Microbe, 2:e13–e22, 2021. doi: $10.1016/S2666-5247(20)30172-5.$

 [32] Jantien A Backer, Don Klinkenberg, and Jacco Wallinga. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 2028 January 2020. Eurosurveillance, 25, 2020. doi: 10.2807/1560-7917.ES.2020.25.5.2000062.

 [33] Stephen A. Lauer, Kyra H. Grantz, Qifang Bi, Forrest K. Jones, Qulu Zheng, Hannah R. Meredith, Andrew S. Azman, Nicholas G. Reich, and Justin Lessler. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation ⁸⁶⁰ and application. Ann Intern Med, 172:577–582, 2020. doi: 10.7326/M20-0504.

 [34] Qun Li, Xuhua Guan, Peng Wu, Xiaoye Wang, Lei Zhou, Yeqing Tong, Ruiqi Ren, Kathy S.M. Leung, Eric H.Y. Lau, Jessica Y. Wong, Xuesen Xing, Nijuan Xiang, Yang Wu, Chao Li, Qi Chen, Dan Li, Tian Liu, Jing Zhao, Man Liu, Wenxiao Tu, Chuding Chen, Lianmei Jin, Rui Yang, Qi Wang, Suhua Zhou, Rui Wang, Hui Liu, Yinbo Luo, Yuan Liu, Ge Shao, Huan Li, Zhongfa Tao, Yang Yang, Zhiqiang Deng, Boxi Liu, Zhitao Ma, Yanping Zhang, Guoqing Shi, Tommy T.Y. Lam, Joseph T. Wu, George F. Gao, Benjamin J. Cowling, Bo Yang, Gabriel M. Leung, and Zijian Feng. Early transmission dynamics in Wuhan, China, of novel coronavirus-⁸⁶⁸ infected pneumonia. N Engl J Med, 382:1199–1207, 2020. doi: 10.1056/NEJMoa2001316.

 [35] Conor McAloon, ine Collins, Kevin Hunt, Ann Barber, Andrew W Byrne, Francis Butler, Miriam Casey, John Griffin, Elizabeth Lane, David McEvoy, Patrick Wall, Martin Green, Luke O'Grady, and Simon J More. Incubation period of COVID-19: A rapid systematic review and meta-analysis of observational research. BMJ Open, 10:e039652, 2020. doi: 10. 873 1136/bmjopen-2020-039652.

 [36] Balram Rai, Anandi Shukla, and Laxmi Kant Dwivedi. Incubation period for COVID-19: A systematic review and meta-analysis. J Public Health, 2021. doi: $10.1007 \div 10.389 - 021 - 01478 - 1$.

 [37] Hualei Xin, Jessica Y Wong, Caitriona Murphy, Amy Yeung, Sheikh Taslim Ali, Peng Wu, and Benjamin J Cowling. The incubation period distribution of coronavirus disease 2019: A systematic review and meta-analysis. Clin Infect Dis, 73:2344–2352, December 2021. doi: 10.1093/cid/ciab501.

 [38] Hideo Tanaka, Tsuyoshi Ogata, Toshiyuki Shibata, Hitomi Nagai, Yuki Takahashi, Masaru Kinoshita, Keisuke Matsubayashi, Sanae Hattori, and Chie Taniguchi. Shorter incubation ⁸⁸² period among COVID-19 cases with the BA.1 Omicron variant. *Int J Environ Res Public* Health, 19:6330, 2022. doi: 10.3390/ijerph19106330.

- [39] Lauren Jansen. Investigation of a SARS-CoV-2 B.1.1.529 (omicron) variant cluster Nebraska, 885 NovemberDecember 2021. MMWR. Morbidity and Mortality Weekly Report, 70, 2021. doi: 10.15585/mmwr.mm705152e3.
- [40] Javier Del guila Meja, Reinhard Wallmann, Jorge Calvo-Montes, Jess Rodrguez-Lozano, Trinidad Valle-Madrazo, and Adrian Aginagalde-Llorente. Secondary attack rate, transmission ⁸⁸⁹ and incubation periods, and serial interval of SARS-CoV-2 Omicron variant, Spain. *Emerg* Infect Dis, 28:1224–1228, 2022. doi: 10.3201/eid2806.220158.
- [41] Mina Park, Colleen Pawliuk, Tribesty Nguyen, Amanda Griffitt, Linda Dix-Cooper, Nadia Fourik, and Martin Dawes. Determining the communicable period of SARS-CoV-2: A rapid ⁸⁹³ review of the literature, March to September 2020. *Euro Surveil*, 26, 2021. doi: 10.2807/ 1560-7917.ES.2021.26.14.2001506.
- [42] Yang Liu, Li-Meng Yan, Lagen Wan, Tian-Xin Xiang, Aiping Le, Jia-Ming Liu, Malik Peiris, ⁸⁹⁶ Leo L M Poon, and Wei Zhang. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis, 20:656–657, 2020. ISSN 14733099. doi: 10.1016/S1473-3099(20)30232-2.
- [43] A. Maisa, G. Spaccaferri, L. Fournier, J. Schaeffer, J. Deniau, P. Rolland, B. Coignard, A. An- drieu, O. Broustal, S. Chene, S. Chent, E. Fougre, G. Gbaguidi, M. Hamidouche, A. Lamy, Q. Mano, B. Mastrovito, A. Mercier, G. Modenesi, G. Picard, J. Prudhomme, F. Rapilly, A. Riondel, M. Rivire, B. Villegas Ramirez, A. Zhu-Soubise, M. Zurbaran, A. Amzert, L. An- dreoletti, A. Bal, R. Beaurepere, S. Behillil, L. Belec, C. Bernard, L. Bocket, L. Bouri, T. Bourlet, C. Bressollette-Bodin, S. Brichler, C. Brugerolles, S. Cado, V. Calvez, N. Capron, S. Castelain, J. Castro-Alvarez, M.-L. Chaix, C. Charpentier, D. Che, C. Chillou, P. Colson, P. Coudene, A. Crinquette, A. De Rougemont, H. Delagrverie, C. Delamare, T. Denecker- Berardino, D. Descamps, M. Desroches, G. Destras, G. Dos Santos, A. Ducancelle, S. Ducreux, T. Duret, V. Enouf, S. Fafi-Kremer, C. Felici, S. Fourati, P.-E. Fournier, C. Gaudy, H. Ger- main, V. Giordanengo, O. Gorge, S. Haim-Boukobza, C. Henquell, A. Holstein, L. Houhamdi, J. Izopet, V. Jacomo, A. Jacques, M.-C. Jaffar-Bandjee, M. Jimenez, L. Josset, S. Kemeny, M.-E. Lafon, A. Le Bars, G. Le Corguille, Q. Lepiller, A. Levasseur, N. Leveque, B. Lina, C. Madelaine, C. Malabat, S. Marque-Juillet, T. Martin-Dunavit, P. Mavingui, A. Merens,

 I. Messak, L. Morand-Joubert, X. Naudot, P. Neybecker, J.-M. Pawlotsky, L. Pilorge, J.-C. Plantier, C. Poggi, M. Pretet, C. Ragot, H. Raoul, S. Rogez, A.-M. Roque-Afonso, B. Roque- bert, D. Rousset, F. Rozenberg, C. Sagot, S. Sahnoune, D. Salgado, O. Sand, C. Saudemont, E. Schvoerer, E. Simon-Loriere, R. Stephan, J. Sudour, V. Thibault, E. Tuaillon, A. Vabret, E. Vallee, S. Van Der Werf, J. Van Helden, L. Verdurme, A. Vignola, D. Wilkinson, and Y. Yazdanpanah. First cases of Omicron in France are exhibiting mild symptoms, November 2021January 2022. Infect Dis Now, 52:160–164, 2022. doi: 10.1016/j.idnow.2022.02.003.

- [44] Andrew A Sayampanathan, Cheryl S Heng, Phua Hwee Pin, Junxiong Pang, Teoh Yee Leong, and Vernon J Lee. Infectivity of asymptomatic versus symptomatic COVID-19. Lancet, 397: 93–94, 2021. doi: 10.1016/S0140-6736(20)32651-9.
- [45] Maimuna S Majumder and Kenneth D Mandl. Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility. Lancet Glob Health, 8:e627–e630, 2020. doi: 10.1016/S2214-109X(20)30113-3.
- [46] Ral Patricio Fernndez-Naranjo, Eduardo Vsconez-Gonzlez, Katherine Simbaa-Rivera, Lenin Gmez-Barreno, Juan S. Izquierdo-Condoy, Domnica Cevallos-Robalino, and Esteban Ortiz- Prado. Statistical data driven approach of COVID-19 in Ecuador: R0 and Rt estimation via new method. Infect Dis Model, 6:232–243, 2021. doi: 10.1016/j.idm.2020.12.012.
- [47] Cheng-Jun Yu, Zi-Xiao Wang, Yue Xu, Ming-Xia Hu, Kai Chen, and Gang Qin. Assessment of basic reproductive number for COVID-19 at global level: A meta-analysis. Medicine, 100: e25837, 2021. doi: 10.1097/MD.0000000000025837.
- [48] Ying Liu and Joacim Rocklv. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med, 28:taab124, 2021. doi: 10.1093/jtm/taab124.
- 935 [49] Talha Khan Burki. Omicron variant and booster COVID-19 vaccines. Lancet Respir Med, 10: e17, 2022. doi: 10.1016/S2213-2600(21)00559-2.
- 937 [50] Ying Liu and Joacim Rockly. The effective reproductive number of the Omicron variant

 of SARS-CoV-2 is several times relative to Delta. J Travel Med, 29:taac037, 2022. doi: 939 $10.1093/jtm/taac037$.

 [51] Yoshiaki Gu, Nobuhiro Komiya, Hajime Kamiya, Yoshinori Yasui, Kiyosu Taniguchi, and Nobuhiko Okabe. Pandemic (H1N1) 2009 transmission during presymptomatic phase, Japan. Emerg Infect Dis, 17:1737–1739, 2011. doi: 10.3201/eid1709.101411.

- [52] F. T. M. Freitas, A. P. S. Cabral, E. N. C. Barros, M. J. O. Burigo, R. D. Prochnow, L. A.
- Silva, M. A. Widdowson, and J. Sobel. Pre-symptomatic transmission of pandemic influenza
- H1N1 2009: investigation of a family cluster, Brazil. Epidemiol Infect, 141:763–766, 2013. doi: 946 10.1017/S0950268812001501.
- [53] J.C. Lopez-Marcos. An upwind scheme for a nonlinear hyperbolic integro-differential equa- μ_{948} tion with integral boundary condition. Comput Math Appl, 22:15–28, 1991. doi: 10.1016/ 0898-1221(91)90030-8.
- [54] Monica Gandhi, Deborah S. Yokoe, and Diane V. Havlir. Asymptomatic transmission, the 951 Achilles heel of current strategies to control Covid-19. N Engl J Med, 382:2158–2160, 2020. doi: 10.1056/NEJMe2009758.
- [55] Luke Taylor. Covid-19: Hong Kong reports worlds highest death rate as zero covid strategy fails. BMJ, page o707, 2022. doi: 10.1136/bmj.o707.